32 results on '"Hl, Y."'
Search Results
2. Pan-cancer analysis of whole genomes
- Author
-
Campbell, P. J. a., Abpemail, Author, Getz, G. b., C, D, Eemail, Author, Korbel, J. O. f., Gemail, Author, Stuart, hEmail Author, J. M., Jennings, J. L. i., Stein, J, L. D. k., Lemail, Author, Perry, M. D. m., Nahal-Bose, N, Ouellette, H. K. n., B. F. F. o., P, C. H. k., Li, Rheinbay, Q, E. b., E, Nielsen, R, Sgroi, G. P. r., D. C. r., Wu, C. -L. r., Faquin, W. C. r., Deshpande, V. r., Boutros, P. C. k., Q, S, Lazar, T, Hoadley, A. J. u., K. A. v., W, Louis, D. N. r., Dursi, L. J. k., Yung, X, Bailey, C. K. n., M. H. y., Z, Saksena, G. b., Raine, Abp, K. M., Buchhalter, Aa, I., Ab, Ac, Kleinheinz, Aa, K., Schlesner, Ac, Aa, M., Zhang, Ad, Wang, J. n., Ae, W., Wheeler, D. A., Af, Ding, Ag, L. y., Z, Simpson, Ah, J. T. k., Ai, O’Connor, B. D. n., Yakneen, Aj, Ellrott, S. g., Ak, K., Miyoshi, Al, N., Butler, Abp, A. P., Royo, Am, R., Shorser, S. I. k., Vazquez, Am, M., Rausch, An, Tiao, T. g., Waszak, G. b., Rodriguez-Martin, S. M. g., Ao, B., Ap, Aq, Shringarpure, Ar, S., D. -Y., As, Demidov, G. M., At, Au, Av, Delaneau, Aw, O., Ax, Ay, Hayashi, Al, S., Imoto, Habermann, N. g., Segre, A. V. b., Garrison, Az, Abp, E., Cafferkey, A. f., Alvarez, E. G., Ao, Heredia-Genestar, J. M., Ba, Muyas, At, F., Drechsel, At, O., Bruzos, Av, A. L., Ao, Temes, Ao, J., Zamora, Ap, Abp, Baez-Ortega, Bb, A., Kim, H. -L., Bc, Mashl, R. J. z., Bd, Ye, Be, K., Dibiase, Bf, Bg, A., Huang, K. -L. z., Letunic, Bh, Bi, I., Mclellan, M. D. y., Z, Ah, Newhouse, S. J. f., Shmaya, As, T., Kumar, Bj, S., Wedge, Bk, D. C., Bl, Abp, Bm, Wright, M. H., Ar, Yellapantula, V. D., Bn, Gerstein, Bo, Bj, M., Bk, Bp, Khurana, Bq, E., Br, Bs, Marques-Bonet, Bt, Bu, T., Bv, Bw, Navarro, Bx, Bu, A., Bustamante, C. D., Ar, Siebert, By, Bz, R., Nakagawa, Ca, Cb, H., Easton, D. F., Cc, Ossowski, Cd, At, S., Tubio, J. M. C., Ao, De La Vega, F. M., Ar, As, By, Estivill, At, X., Yuen, Ce, Mihaiescu, D. k., Omberg, G. L. n., Cf, L., Ferretti, V. n., Sabarinathan, Cg, Ch, R., Ci, Cj, Pich, Ch, O., Gonzalez-Perez, Cj, Ch, A., Taylor-Weiner, Cj, Ck, A., Fittall, M. W., Cl, Demeulemeester, Cl, J., Tarabichi, Cm, Cl, M., Abp, Roberts, Abp, N. D., Van, Loo, Cl, P., Cortés-Ciriano, Cm, Cn, I., Co, Cp, Urban, L. f., Park, G, Co, P., Zhu, Cp, Cq, B., Pitkänen, E. g., Abp, Y., Saini, Cr, N., Klimczak, L. J., Cs, Weischenfeldt, J. g., Ct, Cu, Sidiropoulos, Cu, N., Alexandrov, L. B., Cv, Abp, Rabionet, At, R., Av, Cw, Escaramis, At, G., Cx, Cy, Bosio, At, Av, Holik, A. Z., At, Susak, At, H., Prasad, Av, Av, A., Erkek, S. g., Calabrese, C. f., Raeder, G, Harrington, B. g., Cz, E., Mayes, Da, S., Turner, Da, D., Juul, Cz, S., Roberts, S. A., Db, Song, Cq, L., Koster, Dc, R., Mirabello, Hua, Cq, X., Tanskanen, T. J., Dd, Tojo, Aq, M., Chen, Bk, J., Aaltonen, De, L. A., Df, Rätsch, Dg, G., Dh, Di, Dj, Dk, Schwarz, Dl, R. F. f., Dm, Dn, Do, Butte, A. J., Dp, Brazma, A. f., Chanock, S. J., Cq, Chatterjee, Dq, N., Stegle, Dr, O. f., G, Harismendy, Ds, Dt, O., Bova, G. S., Du, Gordenin, D. A., Cr, Haan, D. h., Sieverling, Dv, L., Feuerbach, Dw, Chalmers, Dx, D., Joly, Dy, Y., Knoppers, Dy, B., Molnár-Gábor, Dz, F., Phillips, Dy, M., Thorogood, Dy, A., Townend, Dy, D., Goldman, Ea, M., Fonseca, N. A. f., Xiang, Eb, Craft, Q. n., Ea, B., Piñeiro-Yáñez, Ec, E., Muñoz, A. f., Petryszak, R. f., Füllgrabe, A. f., Al-Shahrour, Ec, F., Keays, M. f., Haussler, Ea, D., Weinstein, Ed, Ee, J., Huber, Ef, Valencia, W. g., Am, A., Papatheodorou, Bw, Zhu, I. f., Ea, J., Fan, Ae, Y., Torrents, Am, D., Bieg, Bw, Eg, M., Chen, Eh, Ei, K., Chong, Ej, Z., Cibulskis, K. b., Eils, Aa, R., Ac, Ek, Fulton, El, R. S. y., Z, Gelpi, Ah, J. L., Am, Gonzalez, Em, S. f., G, Gut, I. G., Av, Hach, Bu, En, F., Heinold, Eo, Ac, Hu, Ep, T., Huang, V. k., Hutter, Eh, B., Eq, Er, Jäger, Aa, N., Jung, Es, J., Ep, Y., Lalansingh, C. k., Leshchiner, I. b., Livitz, D. b., E. Z., Ep, Maruvka, Y. E. b., R, Et, Milovanovic, Nielsen, M. M., Eu, Paramasivam, Pedersen, Eh, J. S., Eu, Puiggròs, Ev, Sahinalp, S. C., Eo, Ew, Ex, Sarrafi, Eo, I., Stewart, Ex, Stobbe, C. b., M. D., Av, Wala, Bu, J. A. b., E, Wang, Ey, J. z., Be, Wendl, Ez, M. z., Fa, Werner, Fb, Aa, J., Fc, Wu, Ep, Z., Xue, Ep, H., Yamaguchi, T. N. k., Bn, V., Davis-Dusenbery, Bo, B. N., Fd, Grossman, R. L., Fe, Ff, Y., Heinold, Fg, M. C., Aa, Hinton, Ac, Abp, J., Jones, Abp, D. R., Menzies, Abp, A., Stebbings, Abp, L., Hess, J. M. b., Rosenberg, Et, M. b., R, Dunford, A. J. b., Gupta, M. b., Imielinski, Fh, M., Meyerson, Fi, M. b., E, Beroukhim, Ey, R. b., E, Reimand, Fj, J. k., Q, Dhingra, Br, P., Favero, Bt, Fk, F., Dentro, Bl, S., Abp, Cl, Wintersinger, Fl, J., Fm, Fn, Rudneva, V. g., Park, J. W., Fo, Hong, E. P., Fo, Heo, S. G., Fo, Kahles, Dg, A., Lehmann, K. -V., Dg, Di, Dj, Fp, Fq, Soulette, C. M., Aj, Shiraishi, Al, Y., Liu, Fr, F., Fs, He, Fr, Y., Demircioğlu, Ft, D., Davidson, Fu, N. R., Dg, Dl, Fp, Greger, L. f., Fv, S., Liu, Fw, Fv, D., Stark, Fw, S. G., Dj, Fp, Fx, Zhang, Fy, Amin, S. B., Fz, Ga, Gb, Bailey, Gc, P., Chateigner, A. n., Frenkel-Morgenstern, Gd, M., Hou, Fv, Y., Huska, Fw, M. R., Dm, Kilpinen, Ge, H., Lamaze, F. C. k., Fv, C., Fw, Li, Fv, X., Marin, Fw, M. G., Aj, Markowski, Dm, J., Nandi, Gf, T., Ojesina, A. I., Gg, Gh, Gi, Pan-Hammarström, Fv, Q., Park, Gj, P. J., Co, Pedamallu, Cp, C. S. b., E, Fj, Su, Fv, H., Tan, Fw, Gf, P., Gk, Gl, Teh, Gm, B. T., Gk, Gl, Gm, Gn, Go, Wang, Fv, J., Xiong, Fw, Ye, Yung, Fw, Zhang, C. n., Zheng, Fr, L., Zhu, Awadalla, Fw, P. k., L, Creighton, C. J., Gp, Fv, K., Yang, Fw, Göke, Ft, J., Zhang, Gq, Fr, Z., Brooks, Gr, A. N. b., Aj, Fittall, Ey, Martincorena, Abp, I., Rubio-Perez, Ch, C., Cj, Gs, Eu, M., Schumacher, S. b., Shapira, Gt, O. b., Ey, Tamborero, Ch, D., Mularoni, Cj, Ch, L., Hornshøj, Cj, Eu, H., Deu-Pons, Cj, J., Muiños, Gu, Ch, F., Bertl, Cj, Eu, J., Guo, Gv, Ev, Q., Gonzalez-Perez, Cj, Gw, Xiang, Gx, Q., Bazant, W. f., Barrera, E. f., Al-Sedairy, S. T., Gy, Aretz, Gz, A., Bell, Ha, C., Betancourt, Hb, M., Buchholz, Hc, C., Calvo, Hd, F., Chomienne, He, C., Dunn, Hf, M., Edmonds, Hg, S., Green, Hh, E., Gupta, Hi, S., C. M., Hh, Jegalian, Hj, K., Hk, N., Hl, Y., Hm, Hn, Nakagama, Ho, H., Nettekoven, Hp, G., Planko, Hp, L., Scott, Hk, D., Shibata, Hq, T., Shimizu, Hr, Hs, K., Stratton, Abp, M. R., Yugawa, Hs, T., Tortora, Ht, G., Vijayraghavan, Hu, Hi, K., Zenklusen, J. C., Hv, Hw, D., B. M., Dy, Aminou, B. n., Bartolome, Am, J., Boroevich, K. A., Cb, Boyce, Hx, Buchanan, R. f., Ak, A., Byrne, N. J. n., Hy, Z., Cho, Hz, S., Choi, Ia, W., Clapham, Abp, P., Dow, M. T., Hy, Eils, X, Ek, J., Farcas, El, Hy, C., Fayzullaev, N. n., Flicek, P. f., Heath, A. P., Ib, Hofmann, Ic, O., J. H., Id, Hudson, T. J., Ie, Hübschmann, If, Ac, D., Do, Ek, Ig, Ih, Ivkovic, Ii, S., Jeon, S. -H., Ia, Jiao, W. k., Kabbe, Dj, Fq, Kerssemakers, J. N. A., Aa, Ia, H., Ij, J., Koscher, Ik, M., Koures, Hy, A., Kovacevic, Ii, M., Lawerenz, El, C., Il, J., Mijalkovic, Mijalkovic-Lazic, A. M., Ii, Miyano, Nastic, Nicholson, Ocana, D. f., Ohi, Al, K., Ohno-Machado, Hy, L., Pihl, T. D., Im, Prinz, Radovic, Ii, P., Short, C. f., Sofia, H. J., Hh, Spring, Fe, J., Struck, A. J., Ak, Tijanic, Ii, N., Vicente, Hv, Z., Williams, Woo, Ia, Y., Wright, A. J. k., Yang, Hv, L., Hamilton, M. P., In, Johnson, T. A., Hx, Kahraman, Io, A., Ip, Iq, Kellis, M. b., Polak, Ir, P. b., C, Sallari, E, Sinnott-Armstrong, R. b., N. b., Ar, Von, Mering, Iq, C., Beltran, Is, Av, S., Gerhard, Bu, D. S., It, Av, M., Trotta, Bu, J. -R., Bu, Whalley, J. P., Bu, Niu, Iu, B., Espiritu, S. M. G. k., Gao, Ez, Y., Lalansingh, Iv, Teague, C. M. k., Abp, J. W., Wendl, M. C. z., Fa, Fb, Abascal, Abp, F., Bader, G. D. l., Bandopadhayay, P. b., Iw, Ix, Barenboim, J. k., Brunak, Iy, S., Carlevaro-Fita, Iz, Ja, J., Jb, Jc, Chakravarty, Jd, D., Chan, Je, C. W. Y., Aa, Choi, Dw, J. K., Jf, Diamanti, Jg, K., Fink, Frigola, Jh, Gu, J., Gambacorti-Passerini, Ji, C., Garsed, D. W., Jj, Haradhvala, N. J. b., Harmanci, R, A. O., Bk, Helmy, Jk, Fm, M., Herrmann, Aa, C., Ac, Jl, Hobolth, Ev, A., Hodzic, Gv, Ex, E., Dv, C., Isaev, Dw, K. k., Q, Izarzugaza, J. M. G., Iy, Jb, R., Juul, Jm, R. I., Eu, Kim, J. b., J. K., Jn, Jan, Komorowskijg, Lanzós, Jo, Jb, A., Jc, Jm, Larsson, Dg, E., Lee, Bk, D., Bk, S., Bk, X., Lin, Z. b., Liu, Jp, E. M., Br, Bt, Jq, Lochovsky, Bj, L., Bk, Gb, Lou, Madsen, Bk, Eu, T., Marchal, Jr, K., Martinez-Fundichely, Js, Br, A., Bs, Bt, Mcgillivray, P. D., Bj, Meyerson, Bk, W., Paczkowska, Jt, Park, M. k., Ju, K., Park, Jv, Jw, K., Pons, Jx, T., Pulido-Tamayo, Jr, S., Reyes-Salazar, Js, Ch, I., Reyna, M. A., Jy, Rubin, M. A., Jm, Jz, Ka, Kb, Kc, Salichos, Sander, Bk, Dg, C., Ey, Kd, Schumacher, Ke, S. E. b., Gt, Shackleton, Jj, M., Shen, Ke, C., Shrestha, Kf, Eo, R., Shuai, S. k., Tsunoda, L, Hx, T., Kg, Kh, Umer, Ki, H. M., Jg, Uusküla-Reimand, Kj, Kk, L., Verbeke, Kl, L. P. C., Js, Wadelius, Km, Kn, C., Wadi, L. k., Warrell, Bj, J., Bk, Wu, Ko, G., Kp, J., Zhang, Ez, X., Zhang, Kq, Bk, Y., Kr, Ks, Zhao, Kt, Z., Zou, Ku, L., Lawrence, M. S. b., R, Hx, Raphael, B. J., Jy, P. J., Gc, Craft, D. b., Goldman, Kv, M. J., Ea, Aburatani, Kw, H., Binder, Kx, H., Dinh, Ky, H. Q., Kz, S. C., Av, Hoffmann, Bu, Kx, S., Ky, La, Imbusch, Lb, C. D., Dv, Kretzmer, Ky, H., Laird, Lb, P. W., Lc, Martin-Subero, J. I., Bw, Nagae, Ld, Kw, G., Shen, Le, Lf, H., Ik, Q., Weichenhan, Lg, D., Zhou, Lf, W., Berman, B. P., Kz, Lh, Li, Brors, Dv, B., Er, Lj, Plass, Lg, C., Akdemir, K. C., Ei, Bowtell, D. D. L., Jj, Burns, K. H., Lk, Busanovich, Ll, J. b., Lm, Chan, Ln, K., Dueso-Barroso, Edwards, P. A., Lo, Etemadmoghadam, Lp, Jj, D., Haber, J. E., Lq, D. T. W., Lr, Ls, Ju, Y. S., Jf, Abp, Kazanov, M. D., Lt, Lu, Lv, Koh, Lw, Y., Kumar, Lx, Lee, K. b., E. A., Ly, J. J. -K., Co, Lynch, Cp, A. G., Lo, Lp, Lz, Macintyre, Lo, G., Markowetz, Lo, F., Navarro, Lp, F. C. P., Bj, Pearson, J. V., Ma, Rippe, Mb, Do, K., Scully, Mc, R., Villasante, Am, I., Waddell, Ma, N., Yang, Mb, Md, L., Yao, Fh, X., Yoon, Me, S. -S., Lx, C. -Z. b., E, Ey, Bergstrom, E. N., Mf, Boot, Gl, A., Covington, Mg, Ag, K., Fujimoto, Cb, A., M. N., Gl, Islam, Mg, S. M. A., Cv, Mcpherson, J. R., Gl, Morganella, Mg, Abp, S., Mustonen, Mh, V., Mi, Mj, A. W. T., Mk, Prokopec, S. D. k., Vázquez-García, Bn, I., Ml, Mm, Abp, Wu, Gl, Y., Yousif, Mg, F. k., Yu, Mn, W., Rozen, S. G., Gl, Gm, Mg, Rudneva, V. A. g., S. S., Ar, D. J., Da, Xia, Mo, T., Atwal, G. k., L, Fn, Chang, D. K., Gc, Cooke, Mp, S. L., Gc, Faltas, B. M., Dl, Haider, S. k., Kaiser, V. B., Mq, Karlić, Mr, R., Kato, Ms, M., Kübler, K. b., E, R, Margolin, Martin, Mt, S., Abp, Nik-Zainal, Mu, S., Mv, Mw, Abp, P’Ng, Semple, C. k., C. A., Mq, Smith, Ak, J., Sun, R. X. k., Thai, K. n., D. W., Mx, Yuan, My, Lo, K., Mt, Mz, Biankin, A. V., Gc, Mp, Na, Garraway, Nb, Ey, L., Grimmond, S. M., Nc, Adams, Abp, D. J., Anur, Nd, P., Cao, Ae, S., Christie, E. L., Jj, Cmero, Ne, M., Nf, Ng, Cun, Nh, Y., Dawson, Abp, K. J., S. C., Bl, Deshwar, A. G., Ni, Donmez, Eo, N., Drews, Ex, R. M., Lo, Gerstung, M. f., G, Ha, Haase, G. b., Cl, K., Jerman, L. g., Nj, Ji, Nk, Y., Jolly, Nl, Cl, C., Nm, J., Lee-Six, Abp, H., Malikic, Eo, S., Mitchell, Ex, T. J., Lp, Abp, Nn, Morris, Q. D., Fn, Oesper, No, Np, L., Peifer, Nh, M., Peto, Nq, M., Rosebrock, D. b., Rubanova, Ai, Y., Salcedo, Fn, Sengupta, A. k., Nr, S., Shi, No, R., Shin, S. J., Fy, Spiro, O. b., Vembu, No, S., Wintersinger, Ns, J. A., Fl, T. -P., Nh, Nt, K., Nu, H., Spellman, Nv, P. T., Nw, Weinstein, J. N., Ee, Chen, Ef, Fujita, Cb, M., Han, Kq, L., Hasegawa, Al, T., Komura, Al, M., Ae, J., Mizuno, Nx, S., Shimizu, Al, E., Ny, Xu, Nz, Y., Yamaguchi, Al, R., No, F., Kq, Y., Yoon, C. J., Jf, Yuan, Liang, Ae, H., Alawi, Oa, M., Borozan, Ob, Brewer, I. k., D. S., Oc, Cooper, Od, C. S., Od, Oe, Of, Desai, N. n., Grundhoff, Oa, A., Iskar, Og, Oh, M., Oi, X., Zapatka, Lichter, Eq, P., Alsop, Oh, Jj, K., Bruxner, T. J. C., Jh, Christ, A. N., Jh, Cordner, S. M., Oj, Cowin, P. A., Ok, Drapkin, Ol, R., Fereday, Ok, S., George, Gb, J., Ok, A., Holmes, Ma, O., Hung, Mb, J. A., Om, Kassahn, On, K. S., Jh, Kazakoff, Oo, S. H., Ma, Kennedy, Mb, C. J., Op, Leonard, Oq, C. R., Ma, Mileshkin, Mb, Jj, L., Miller, D. K., Jh, Mp, Or, Arnau, G. M., Ok, Mitchell, Ok, C., Newell, Ma, F., Nones, Mb, Ma, K., Patch, Mb, A. -M., Ma, Quinn, Mb, M. C., Ma, Taylor, Mb, D. F., Jh, Thorne, Ok, H., Traficante, Ok, N., Vedururu, Ok, R., N. M., Mb, Waring, P. M., Os, Wood, Ma, S., Mb, Xu, Ma, Q., Defazio, Mb, Ot, A., Ou, Ov, Anderson, M. J., Jh, Antonello, Ow, D., Barbour, A. P., Ox, Bassi, Oy, Ow, C., Bersani, Oz, S., Cataldo, Oz, I., Chantrill, Pa, L. A., Mp, Chiew, Pb, Y. -E., Ot, Chou, Mp, A., Cingarlini, Pc, Ht, S., Cloonan, Pd, N., Corbo, Pa, V., Davi, Pe, M. V., Pf, Duthie, F. R., Gc, Gill, Pg, A. J., Mp, Graham, Pc, J. S., Gc, Harliwong, Ph, Jh, I., Jamieson, N. B., Gc, Nb, Pi, Johns, A. L., Mp, Kench, Or, J. G., Mp, Pc, Pj, Landoni, Ow, L., Lawlor, R. T., Pa, Mafficini, Pa, A., Merrett, N. D., Ow, Miotto, Pk, Ow, M., Musgrove, E. A., Gc, Nagrial, A. M., Mp, Oien, K. A., Os, Pajic, Pl, Mp, M., Pinese, Pm, M., Robertson, A. J., Jh, Rooman, Mp, I., Rusev, B. C., Pa, Samra, J. S., Ow, Scardoni, Pc, Oz, M., Scarlett, C. J., Mp, Scarpa, Pn, Sereni, Ow, E., Sikora, K. O., Pa, Simbolo, Pe, M., Taschuk, M. L. n., Toon, C. W., Mp, Vicentini, Pa, C., Mp, J., Zeps, Po, N., Behren, Pp, Pq, A., Burke, Pr, H., Cebon, Pq, J., Dagg, R. A., Ps, Paoli-Iseppi, De, Pt, R., Dutton-Regester, Field, M. A., Pu, Fitzgerald, Pv, A., Hersey, Pr, P., Jakrot, Pr, V., Johansson, P. A., Ma, Kakavand, Pt, H., Kefford, R. F., Pw, Lau, L. M. S., Px, Long, G. V., Py, Pickett, H. A., Px, Pritchard, A. L., Ma, Pupo, G. M., Pz, Saw, R. P. M., Py, Schramm, S. -J., Qa, Shang, C. A., Pv, Py, P., Spillane, A. J., Py, Stretch, J. R., Py, Tembe, Ot, V., Thompson, Qa, J. F., Py, Vilain, R. E., Qb, Wilmott, J. S., Py, J. Y., Qc, Hayward, N. K., Ma, Mann, Pr, G. J., Ot, Scolyer, Qd, R. A., Ou, Py, Qb, Bartlett, Qe, Qf, J., Bavi, Qg, Qh, P., Chadwick, D. E., Qi, Chan-Seng-Yue, Qh, M., Cleary, Qh, S., Connor, Qj, A. A., Qj, Czajka, Qk, If, K., Denroche, R. E., Qh, Dhani, N. C., Ql, Eagles, If, J., Gallinger, Qj, Qk, Grant, R. C., Qh, Hedley, Qk, Ql, D., Hollingsworth, M. A., Qm, Jang, G. H., Qh, Kalimuthu, S. -B., Qn, Lungu, Qh, I., Luo, Qo, Mbabaali, X. k., If, F., T. A., Qk, J. K., If, Moore, M. J., Ql, Notta, Qh, F., Pasternack, Qp, If, D., Petersen, G. M., Qq, Roehrl, M. H. A. q., Qh, Qr, Qs, Qt, Sam, If, M., Selander, Qk, I., Serra, Os, S., Shahabi, Qn, S., Thayer, S. P., Qm, Timms, L. E., If, Wilson, G. W. k., Wilson, Qh, J. M., Qh, Wouters, B. G., Qu, J. D., If, Qh, Qv, Beck, T. A. n., Bhandari, Qw, Collins, V. k., C. C., Eo, Fleshner, N. E., Qx, Fox, N. S. k., Fraser, M. k., Heisler, L. E., Qy, Lalonde, E. k., Livingstone, J. k., Meng, Qz, A., Sabelnykova, V. Y. k., Shiah, Y. -J. k., Van der Kwast, Ra, T., Bristow, R. G. q., Rb, Rc, Rd, Re, Ding, Rf, S., Rg, D., Fv, L., Nie, Rg, Y., Xiao, Rh, Xing, Hm, R., Yang, Ri, Rj, Y., Banks, R. E., Rk, Bourque, Rl, G., Brennan, Rm, Rn, P., Letourneau, Ro, L., Riazalhosseini, Rm, Y., Scelo, Rn, G., Vasudev, Rk, N., Viksna, Rp, Rq, J., Lathrop, Rm, M., Tost, Rr, J., Ahn, S. -M., Rs, Aparicio, Rt, S., Arnould, Ru, L., Aure, M. R., Rv, Bhosle, Abp, S. G., Birney, E. f., Borg, Rw, A., Boyault, Rx, S., Brinkman, A. B., Ry, Brock, J. E., Rz, Broeks, Sa, A., Børresen-Dale, A. -L., Rv, Caldas, Sb, C., Chin, Sc, S. -F., Sb, Davies, Sc, Mu, H., Abp, Mv, Desmedt, Sd, C., Dirix, Se, Sf, L., Dronov, Ehinger, Sg, A., Eyfjord, J. E., Sh, Fatima, Gt, A., Foekens, J. A., Si, Futreal, P. A., Sj, Garred, Sk, Ø., Giri, Sl, D. D., Sm, Glodzik, Abp, D., Grabau, Sn, D., Hilmarsdottir, Sh, H., Hooijer, G. K., So, Jacquemier, Sp, J., S. J., Sq, Jonasson, J. G., Sh, Jonkers, Sr, J., H. -Y., Sp, King, T. A., Ss, Knappskog, St, Su, S., Abp, Kong, Sp, G., Krishnamurthy, Sv, S., Lakhani, S. R., Sw, Langerød, Rv, A., Larsimont, Sx, D., H. J., Sq, J. -Y., Sy, M. T. M., Sj, Lingjærde, O. C., Sz, Macgrogan, Ta, G., Martens, J. W. M., Si, O’Meara, Pauporté, He, I., Pinder, Tb, S., Pivot, Tc, X., Provenzano, Td, E., Purdie, C. A., Te, Ramakrishna, Abp, M., Ramakrishnan, Abp, K., Reis-Filho, Sm, J., Richardson, A. L., Gt, Ringnér, Rw, M., Rodriguez, J. B., Am, Rodríguez-González, F. G., Iz, Romieu, Tf, G., Salgado, Os, R., Sauer, Sz, T., Shepherd, Abp, R., Sieuwerts, A. M., Si, Simpson, P. T., Sw, Smid, Si, M., Sotiriou, Span, P. N., Tg, Stefánsson, Ó. A., Th, Stenhouse, Ti, A., Stunnenberg, H. G., Fw, Sweep, Tj, Tk, F., Tan, B. K. T., Tl, Thomas, Tm, G., Thompson, A. M., Ti, Tommasi, Tn, S., Treilleux, To, I., Tutt, Tp, Ueno, N. T., Nv, Van, Laere, Sf, S., Van den Eynden, G. G., Sf, Vermeulen, Sf, P., Viari, Vincent-Salomon, Tj, A., Wong, B. H., Tq, Yates, Abp, X., Van, Deurzen, C. H. M., Tr, van de Vijver, M. J., Os, Van’T, Veer, Ts, L., Ammerpohl, Tt, O., Tu, Tv, Aukema, Tu, S., Tv, Tw, Bergmann, A. K., Tx, Bernhart, S. H., Kx, Ky, Lb, Borkhardt, Ty, A., Borst, Tz, C., Burkhardt, Ua, B., Claviez, Ub, A., Goebler, M. E., Uc, Haake, Tt, A., Haas, Tz, S., Hansmann, Ud, M., Hoell, J. I., Ty, Hummel, Ue, M., Karsch, Uf, D., Klapper, Tw, W., Kneba, Uf, M., Kreuz, Ug, M., Kube, Uh, D., Küppers, Ui, R., Lenze, Ue, D., Loeffler, López, Ca, C., Mantovani-Löffler, Tt, Uj, L., Möller, Uk, P., Ott, Ul, G., Radlwimmer, Oh, B., Richter, Tt, J., Rohde, Tw, Um, M., Rosenstiel, P. C., Un, Rosenwald, Uo, A., Schilhabel, M. B., Un, Schreiber, Up, S., Stadler, P. F., Kx, Staib, Uq, P., Stilgenbauer, Ur, S., Sungalee, S. g., Szczepanowski, Tw, M., Toprak, U. H., Ac, Trümper, Us, L. H. P., Uh, Wagener, Ca, R., Zenz, Tt, Er, T., Hovestadt, Oh, V., Von, Kalle, Do, C., Kool, Korshunov, Lr, Ik, A., Landgraf, Ut, P., Lehrach, Uu, Uv, H., Northcott, P. A., Uw, Pfister, S. M., Ik, Lr, Ux, Reifenberger, Uu, G., Warnatz, H. -J., Uv, Wolf, Uy, S., Yaspo, M. -L., Uv, Assenov, Uz, Y., Gerhauser, Minner, Va, S., Schlomm, Ct, T., Simon, Vb, Vc, R., Sauter, Vc, G., Sültmann, Er, H., Biswas, Vd, N. K., Ve, Maitra, Ve, A., Majumder, P. P., Ve, Sarin, Vf, R., Barbi, Pe, S., Bonizzato, Pa, G., Cantù, Dei, Tos, A. P., Vg, Fassan, Vh, M., Grimaldi, Pa, S., Luchini, Oz, C., Malleo, Ow, G., Marchegiani, Milella, Michele, Ht, M., Paiella, Ow, S., Pea, Ow, A., Pederzoli, Ow, P., Ruzzenente, Salvia, Ow, R., Sperandio, Pa, N., Arai, Hq, Y., Hama, Hq, N., Hiraoka, Vi, N., Hosoda, Hq, F., Nakamura, Hq, H., Ojima, Vj, H., Okusaka, Vk, T., Totoki, Urushidate, Hr, T., Fukayama, Vl, M., Ishikawa, Vm, S., Katai, Vn, H., Katoh, Vm, H., Vm, D., Rokutan, Ms, H., Saito-Adachi, Suzuki, Kw, A., Taniguchi, Vo, Vp, H., Tatsuno, Kw, K., Ushiku, Vl, T., Yachida, Hq, S., Yamamoto, Vq, Kw, S., Aikata, Vr, H., Arihiro, Vr, K., Ariizumi, S. -I., Vs, Chayama, Furuta, Gotoh, Vt, K., Hayami, Vu, S., Hirano, Vv, S., Kawakami, Vr, Y., Maejima, Cb, K., Vv, T., Nakano, Ohdan, Sasaki-Oku, Tanaka, Al, H., Vu, M., Yamamoto, Vs, M., Yamaue, Vu, H., Choo, S. P., Vw, Cutcutache, Gl, I., Khuntikeo, Mg, Ow, N., Ong, Vx, C. K., Vy, Pairojkul, Os, C., Popescu, Vz, I., K. S., Wa, Aymerich, Wb, M., Lopez-Guillermo, Wc, A., López-Otín, Wd, C., Puente, X. S., Wd, Campo, We, E., Amary, Wf, Wg, F., Baumhoer, Wh, D., Behjati, Bjerkehagen, Wh, B., Futreal, Wi, Myklebost, Su, O., Pillay, Wj, N., Tarpey, Wk, P., Tirabosco, Wl, R., Zaikova, Wm, O., Flanagan, A. M., Wn, Boultwood, Wo, J., Bowen, Abp, D. T., Cazzola, Wp, M., A. R., Lp, Hellstrom-Lindberg, Wq, E., Malcovati, Wp, L., Nangalia, Wr, J., Papaemmanuil, Vyas, Ma, P., Ang, Ws, Wt, Y., Barr, Wu, H., Beardsmore, Wv, D., Eldridge, Lo, M., Gossage, Ww, J., Grehan, Mv, N., Hanna, G. B., Wx, Hayes, S. J., Wy, Hupp, Wz, T. R., Xa, Khoo, Xb, D., Lagergren, Wq, J., Lovat, Xc, L. B., Ge, Macrae, Ee, S., O’Donovan, Mv, M., O’Neill, J. R., Xd, Parsons, S. L., Xe, Preston, S. R., Xf, Puig, Xg, S., Roques, Xh, T., Sanders, G. w., Sothi, Xi, S., Tavaré, Lo, S., Tucker, Xj, O., Turkington, Xk, R., Underwood, T. J., Xl, Welch, Xm, I., R. C., Mv, Berney, D. M., Xn, Bono, De, J. S., Oe, Cahill, Xo, D., Camacho, Oe, N., Dennis, N. M., Xo, Dudderidge, Xo, T., Edwards, Xp, S. E., Oe, Fisher, Xo, C., Foster, C. S., Xq, Ghori, Xr, Gill, Ws, P., Gnanapragasam, V. J., Nn, Gundem, Xs, Jq, G., Hamdy, F. C., Xt, Hawkins, Hazell, Xo, S., Howat, Nn, W., Isaacs, W. B., Xu, Karaszi, Ws, K., Kay, J. D., Ge, Xo, V., Kote-Jarai, Oe, Z., Kremeyer, Abp, B., Xo, P., Lambert, Ws, A., Leongamornlert, D. A., Oe, Abp, Livni, Xo, N., Y. -J., Xn, Luxton, Xv, H. J., Ge, Marsden, Ws, L., Massie, C. E., Lo, Matthews, Oe, L., Mayer, Xo, E., Mcdermott, Xw, Abp, U., Merson, Oe, S., Neal, D. E., Lo, Nn, Ng, Xx, A., Nicol, Ogden, Rowe, E. W., Xo, Shah, N. C., Nn, Xo, A., Verrill, Ws, C., Visakorpi, Xy, Du, T., Warren, A. Y., Nn, Whitaker, Xz, H. C., Ge, Xv, H., Van, As, Eeles, R. A., Oe, Abeshouse, Xo, Jq, A., Agrawal, Fe, N., Akbani, Mv, R., Al-Ahmadie, Ya, Jq, H., Albert, Qg, M., Aldape, Oi, K., Ally, Yb, Yc, A., Appelbaum, E. L. z., Armenia, Ge, Yd, J., Asa, Xe, S., Auman, Ye, J. T., Yf, Balasundaram, Yc, M., Balu, S. w., Barnholtz-Sloan, Yg, J., Bathe, Yh, O. F., Yi, Baylin, Yj, S. B., Dr, Benz, Xp, Yk, C., Berchuck, Yl, A., Berrios, Ym, M., Bigner, Yn, D., Birrer, M. r., Bodenheimer, T. w., Boice, Xg, L., Bootwalla, M. S., Ym, Bosenberg, Yo, M., Bowlby, Yc, R., Boyd, Yp, J., Broaddus, R. R., Oi, Yq, M., Brooks, Yc, D., Bullman, S. b., Caesar-Johnson, Fj, S. J., Hv, Carey, T. E., Yr, Carlsen, Cerfolio, Ys, R., Chandan, V. S., Yt, H. -W., Wt, Cherniack, Yd, A. D. b., Ey, Chien, Fj, Yu, J., Cho, J. b., Chuah, Yc, E., Cibulskis, C. b., Cope, Yv, L., Cordes, M. G. z., Curley, Xh, Yw, E., Czerniak, Oi, B., Danilova, Xb, Davis, I. J., Yx, Defreitas, T. b., Demchok, J. A., Hv, Dhalla, Yc, N., Dhir, Yy, R., Doddapaneni, H. V., Ag, El-Naggar, Oi, A., Felau, Xb, Hv, I., Ferguson, M. L., Yz, Finocchiaro, Za, G., Fong, K. M., Zb, Frazer, S. b., Friedman, Zc, W., Fronick, C. C. z., Fulton, Xh, Gabriel, L. A. z., Gao, S. B. b., Gehlenborg, N. b., Gershenwald, Zd, J. E., Ze, Ghossein, Zf, Sm, R., Giama, N. H., Zg, Gibbs, R. A., Ag, Gomez, Zh, C., Govindan, R. y., Hayes, D. N. w., Zi, Zj, Hegde, A. M., Ee, Heiman, Ef, Heins, D. I. b., Jq, Z., Hepperla, A. J. w., Holbrook, Ym, A., Holt, R. A., Yc, Hoyle, A. P. w., Hruban, R. H., Yv, Ag, J., Xg, M., Huntsman, Zk, D., Huse, Jq, J., Iacobuzio-Donahue, C. A., Sm, Ittmann, Zl, M., Jayaseelan, Zm, J. C., Ag, Jefferys, S. R. w., C. D., Zn, S. J. M., Zo, Juhl, Zp, H., Kang, K. J., Zq, Karlan, Zr, B., Kasaian, Zo, K., Kebebew, Zs, E., Kim, Zt, H. K., Zu, Korchina, Ag, V., Kundra, Wt, R., Lai, Yd, P. H., Ym, Lander, E. b., Zv, X., Levine, D. A., Jq, Lewis, Zw, Ag, L., Ley, Zx, T., H. I., Yc, Lin, P. b., Linehan, W. M., Zy, F. F., No, Ef, Y., Lype, Zz, L., Yc, Y., Maglinte, D. T., Ym, Aaa, Mardis, E. R. z., Yp, Aab, Marks, Ow, J., Aac, Marra, M. A., Yc, Matthew, T. J., Aj, Mayo, Mccune, Aad, K., Meier, S. R. b., Meng, S. w., Mieczkowski, P. A. v., Mikkelsen, Aae, T., Miller, C. A. z., Mills, Aaf, G. B., Morrison, Aag, Mose, Moser, L. E. w., C. D., Zg, Mungall, A. J., Yc, Yc, K., Mutch, Aah, D., Muzny, Aai, D. M., Myers, Aaj, J., Newton, Aj, Y., Noble, M. S. b., O’Donnell, Aak, P., Aal, B. P., Ochoa, Aam, J. -W., Parker, Aan, J. S., Pass, Aao, H., Pastore, Pennell, Aap, N. A., Perou, Aaq, C. M., Petrelli, Aar, N., Potapova, Aas, O., Rader, Aat, J. S., Ramalingam, Aau, S., Rathmell, Aav, W. K., Reuter, Sm, V., Reynolds, S. M., Zz, Ringel, Aaw, M., Roach, Aax, J., L. R., Zg, A. G., Yc, Sadeghi, Yc, S., Saller, Aay, C., Sanchez-Vega, Wt, F., Schadendorf, Yd, Eq, D., Aaz, Schein, J. E., Yc, Schmidt, H. K. z., Schultz, Yd, N., Seethala, Aba, R., Senbabaoglu, Dg, Y., Shelton, Yw, T., Shi, Y. w., Shih, J. b., Shmulevich, Fj, Zz, I., Shriver, Abb, C., Signoretti, Fj, S., Abc, Jb, Simons, J. V. w., Singer, Abd, Sipahimalani, Yc, P., Skelly, T. J. v., Smith-McCune, Socci, N. D., Dg, Soloway, Aan, M. G., Sood, Abe, A. K., Tam, Tan, D. v., Tarnuzzer, Hv, R., Thiessen, Abf, R. H., L. B., Xg, Tsao, Xe, M., Umbricht, Ye, Lk, C., Abg, Wv, Van Den Berg, D. J., Ym, Van, Meir, Abh, E. G., Veluvolu, U. v., Voet, D. b., Weinberger, Abi, P., Weisenberger, Wigle, Abj, D., Wilkerson, M. D. v., Wilson, R. K. z., Abk, Winterhoff, Abl, B., Wiznerowicz, Abm, M., Abn, Wong, T. z., Yc, Abo, W., Yau, Zhang, H. b., Yd, H., Hv, J., The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium View Correspondence (jump link), Medical Oncology, Pathology, IBM, Pharmacyclics, Novartis, Celgene, AstraZeneca, Bayer, Janssen Biotech, University of Chicago, Ipsen, Pfizer, Ono Pharmaceutical, Ariad Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, University of St Andrews. School of Medicine, University of St Andrews. Statistics, University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Cellular Medicine Division, RS: CAPHRI - R4 - Health Inequities and Societal Participation, Metamedica, Háskóli Íslands, University of Iceland, Faculty of Medicine, University of Helsinki, Department of Medical and Clinical Genetics, Research Programs Unit, Lauri Antti Aaltonen / Principal Investigator, ATG - Applied Tumor Genomics, Helsinki Institute of Life Science HiLIFE, Organismal and Evolutionary Biology Research Programme, Helsinki Institute for Information Technology, Institute of Biotechnology, Bioinformatics, Department of Computer Science, STEMM - Stem Cells and Metabolism Research Program, Centre of Excellence in Stem Cell Metabolism, Genome-Scale Biology (GSB) Research Program, Department of Physics, HUS Helsinki and Uusimaa Hospital District, University of Zurich, ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Apollo - University of Cambridge Repository, Graduate School, Laboratory Genetic Metabolic Diseases, AGEM - Endocrinology, metabolism and nutrition, AGEM - Inborn errors of metabolism, CCA - Cancer biology and immunology, Campbell, P, Getz, G, Korbel, J, Stuart, J, Jennings, J, Stein, L, Perry, M, Nahal-Bose, H, Ouellette, B, Li, C, Rheinbay, E, Nielsen, G, Sgroi, D, Wu, C, Faquin, W, Deshpande, V, Boutros, P, Lazar, A, Hoadley, K, Louis, D, Dursi, L, Yung, C, Bailey, M, Saksena, G, Raine, K, Buchhalter, I, Kleinheinz, K, Schlesner, M, Zhang, J, Wang, W, Wheeler, D, Ding, L, Simpson, J, O'Connor, B, Yakneen, S, Ellrott, K, Miyoshi, N, Butler, A, Royo, R, Shorser, S, Vazquez, M, Rausch, T, Tiao, G, Waszak, S, Rodriguez-Martin, B, Shringarpure, S, Wu, D, Demidov, G, Delaneau, O, Hayashi, S, Imoto, S, Habermann, N, Segre, A, Garrison, E, Cafferkey, A, Alvarez, E, Heredia-Genestar, J, Muyas, F, Drechsel, O, Bruzos, A, Temes, J, Zamora, J, Baez-Ortega, A, Kim, H, Mashl, R, Ye, K, Dibiase, A, Huang, K, Letunic, I, Mclellan, M, Newhouse, S, Shmaya, T, Kumar, S, Wedge, D, Wright, M, Yellapantula, V, Gerstein, M, Khurana, E, Marques-Bonet, T, Navarro, A, Bustamante, C, Siebert, R, Nakagawa, H, Easton, D, Ossowski, S, Tubio, J, De La Vega, F, Estivill, X, Yuen, D, Mihaiescu, G, Omberg, L, Ferretti, V, Sabarinathan, R, Pich, O, Gonzalez-Perez, A, Taylor-Weiner, A, Fittall, M, Demeulemeester, J, Tarabichi, M, Roberts, N, Van Loo, P, Cortes-Ciriano, I, Urban, L, Park, P, Zhu, B, Pitkanen, E, Li, Y, Saini, N, Klimczak, L, Weischenfeldt, J, Sidiropoulos, N, Alexandrov, L, Rabionet, R, Escaramis, G, Bosio, M, Holik, A, Susak, H, Prasad, A, Erkek, S, Calabrese, C, Raeder, B, Harrington, E, Mayes, S, Turner, D, Juul, S, Roberts, S, Song, L, Koster, R, Mirabello, L, Hua, X, Tanskanen, T, Tojo, M, Chen, J, Aaltonen, L, Ratsch, G, Schwarz, R, Butte, A, Brazma, A, Chanock, S, Chatterjee, N, Stegle, O, Harismendy, O, Bova, G, Gordenin, D, Haan, D, Sieverling, L, Feuerbach, L, Chalmers, D, Joly, Y, Knoppers, B, Molnar-Gabor, F, Phillips, M, Thorogood, A, Townend, D, Goldman, M, Fonseca, N, Xiang, Q, Craft, B, Pineiro-Yanez, E, Munoz, A, Petryszak, R, Fullgrabe, A, Al-Shahrour, F, Keays, M, Haussler, D, Weinstein, J, Huber, W, Valencia, A, Papatheodorou, I, Zhu, J, Fan, Y, Torrents, D, Bieg, M, Chen, K, Chong, Z, Cibulskis, K, Eils, R, Fulton, R, Gelpi, J, Gonzalez, S, Gut, I, Hach, F, Heinold, M, Hu, T, Huang, V, Hutter, B, Jager, N, Jung, J, Kumar, Y, Lalansingh, C, Leshchiner, I, Livitz, D, Ma, E, Maruvka, Y, Milovanovic, A, Nielsen, M, Paramasivam, N, Pedersen, J, Puiggros, M, Sahinalp, S, Sarrafi, I, Stewart, C, Stobbe, M, Wala, J, Wang, J, Wendl, M, Werner, J, Wu, Z, Xue, H, Yamaguchi, T, Davis-Dusenbery, B, Grossman, R, Kim, Y, Hinton, J, Jones, D, Menzies, A, Stebbings, L, Hess, J, Rosenberg, M, Dunford, A, Gupta, M, Imielinski, M, Meyerson, M, Beroukhim, R, Reimand, J, Dhingra, P, Favero, F, Dentro, S, Wintersinger, J, Rudneva, V, Park, J, Hong, E, Heo, S, Kahles, A, Lehmann, K, Soulette, C, Shiraishi, Y, Liu, F, He, Y, Demircioglu, D, Davidson, N, Greger, L, Li, S, Liu, D, Stark, S, Zhang, F, Amin, S, Bailey, P, Chateigner, A, Frenkel-Morgenstern, M, Hou, Y, Huska, M, Kilpinen, H, Lamaze, F, Li, X, Liu, X, Marin, M, Markowski, J, Nandi, T, Ojesina, A, Pan-Hammarstrom, Q, Pedamallu, C, Su, H, Tan, P, Teh, B, Xiong, H, Ye, C, Zhang, X, Zheng, L, Zhu, S, Awadalla, P, Creighton, C, Wu, K, Yang, H, Goke, J, Zhang, Z, Brooks, A, Martincorena, I, Rubio-Perez, C, Juul, M, Schumacher, S, Shapira, O, Tamborero, D, Mularoni, L, Hornshoj, H, Deu-Pons, J, Muinos, F, Bertl, J, Guo, Q, Bazant, W, Barrera, E, Al-Sedairy, S, Aretz, A, Bell, C, Betancourt, M, Buchholz, C, Calvo, F, Chomienne, C, Dunn, M, Edmonds, S, Green, E, Gupta, S, Hutter, C, Jegalian, K, Jones, N, Lu, Y, Nakagama, H, Nettekoven, G, Planko, L, Scott, D, Shibata, T, Shimizu, K, Stratton, M, Yugawa, T, Tortora, G, Vijayraghavan, K, Zenklusen, J, Aminou, B, Bartolome, J, Boroevich, K, Boyce, R, Buchanan, A, Byrne, N, Chen, Z, Cho, S, Choi, W, Clapham, P, Dow, M, Eils, J, Farcas, C, Fayzullaev, N, Flicek, P, Heath, A, Hofmann, O, Hong, J, Hudson, T, Hubschmann, D, Ivkovic, S, Jeon, S, Jiao, W, Kabbe, R, Kerssemakers, J, Kim, J, Koscher, M, Koures, A, Kovacevic, M, Lawerenz, C, Liu, J, Mijalkovic, S, Mijalkovic-Lazic, A, Miyano, S, Nastic, M, Nicholson, J, Ocana, D, Ohi, K, Ohno-Machado, L, Pihl, T, Prinz, M, Radovic, P, Short, C, Sofia, H, Spring, J, Struck, A, Tijanic, N, Vicente, D, Wang, Z, Williams, A, Woo, Y, Wright, A, Yang, L, Hamilton, M, Johnson, T, Kahraman, A, Kellis, M, Polak, P, Sallari, R, Sinnott-Armstrong, N, von Mering, C, Beltran, S, Gerhard, D, Gut, M, Trotta, J, Whalley, J, Niu, B, Espiritu, S, Gao, S, Huang, Y, Teague, J, Abascal, F, Bader, G, Bandopadhayay, P, Barenboim, J, Brunak, S, Carlevaro-Fita, J, Chakravarty, D, Chan, C, Choi, J, Diamanti, K, Fink, J, Frigola, J, Gambacorti Passerini, C, Garsed, D, Haradhvala, N, Harmanci, A, Helmy, M, Herrmann, C, Hobolth, A, Hodzic, E, Hong, C, Isaev, K, Izarzugaza, J, Johnson, R, Juul, R, Jan, K, Lanzos, A, Larsson, E, Lee, D, Lin, Z, Liu, E, Lochovsky, L, Lou, S, Madsen, T, Marchal, K, Martinez-Fundichely, A, Mcgillivray, P, Meyerson, W, Paczkowska, M, Park, K, Pons, T, Pulido-Tamayo, S, Reyes-Salazar, I, Reyna, M, Rubin, M, Salichos, L, Sander, C, Shackleton, M, Shen, C, Shrestha, R, Shuai, S, Tsunoda, T, Umer, H, Uuskula-Reimand, L, Verbeke, L, Wadelius, C, Wadi, L, Warrell, J, Wu, G, Yu, J, Zhang, Y, Zhao, Z, Zou, L, Lawrence, M, Raphael, B, Craft, D, Aburatani, H, Binder, H, Dinh, H, Heath, S, Hoffmann, S, Imbusch, C, Kretzmer, H, Laird, P, Martin-Subero, J, Nagae, G, Shen, H, Wang, Q, Weichenhan, D, Zhou, W, Berman, B, Brors, B, Plass, C, Akdemir, K, Bowtell, D, Burns, K, Busanovich, J, Chan, K, Dueso-Barroso, A, Edwards, P, Etemadmoghadam, D, Haber, J, Ju, Y, Kazanov, M, Koh, Y, Kumar, K, Lee, E, Lee, J, Lynch, A, Macintyre, G, Markowetz, F, Navarro, F, Pearson, J, Rippe, K, Scully, R, Villasante, I, Waddell, N, Yao, X, Yoon, S, Zhang, C, Bergstrom, E, Boot, A, Covington, K, Fujimoto, A, Huang, M, Islam, S, Mcpherson, J, Morganella, S, Mustonen, V, Ng, A, Prokopec, S, Vazquez-Garcia, I, Wu, Y, Yousif, F, Yu, W, Rozen, S, Xia, T, Atwal, G, Chang, D, Cooke, S, Faltas, B, Haider, S, Kaiser, V, Karlic, R, Kato, M, Kubler, K, Margolin, A, Martin, S, Nik-Zainal, S, P'Ng, C, Semple, C, Smith, J, Sun, R, Thai, K, Wright, D, Yuan, K, Biankin, A, Garraway, L, Grimmond, S, Adams, D, Anur, P, Cao, S, Christie, E, Cmero, M, Cun, Y, Dawson, K, Deshwar, A, Donmez, N, Drews, R, Gerstung, M, Ha, G, Haase, K, Jerman, L, Ji, Y, Jolly, C, Lee-Six, H, Malikic, S, Mitchell, T, Morris, Q, Oesper, L, Peifer, M, Peto, M, Rosebrock, D, Rubanova, Y, Salcedo, A, Sengupta, S, Shi, R, Shin, S, Spiro, O, Vembu, S, Yang, T, Yu, K, Zhu, H, Spellman, P, Chen, Y, Fujita, M, Han, L, Hasegawa, T, Komura, M, Li, J, Mizuno, S, Shimizu, E, Wang, Y, Xu, Y, Yamaguchi, R, Yang, F, Yang, Y, Yoon, C, Yuan, Y, Liang, H, Alawi, M, Borozan, I, Brewer, D, Cooper, C, Desai, N, Grundhoff, A, Iskar, M, Su, X, Zapatka, M, Lichter, P, Alsop, K, Bruxner, T, Christ, A, Cordner, S, Cowin, P, Drapkin, R, Fereday, S, George, J, Hamilton, A, Holmes, O, Hung, J, Kassahn, K, Kazakoff, S, Kennedy, C, Leonard, C, Mileshkin, L, Miller, D, Arnau, G, Mitchell, C, Newell, F, Nones, K, Patch, A, Quinn, M, Taylor, D, Thorne, H, Traficante, N, Vedururu, R, Waring, P, Wood, S, Xu, Q, Defazio, A, Anderson, M, Antonello, D, Barbour, A, Bassi, C, Bersani, S, Cataldo, I, Chantrill, L, Chiew, Y, Chou, A, Cingarlini, S, Cloonan, N, Corbo, V, Davi, M, Duthie, F, Gill, A, Graham, J, Harliwong, I, Jamieson, N, Johns, A, Kench, J, Landoni, L, Lawlor, R, Mafficini, A, Merrett, N, Miotto, M, Musgrove, E, Nagrial, A, Oien, K, Pajic, M, Pinese, M, Robertson, A, Rooman, I, Rusev, B, Samra, J, Scardoni, M, Scarlett, C, Scarpa, A, Sereni, E, Sikora, K, Simbolo, M, Taschuk, M, Toon, C, Vicentini, C, Wu, J, Zeps, N, Behren, A, Burke, H, Cebon, J, Dagg, R, De Paoli-Iseppi, R, Dutton-Regester, K, Field, M, Fitzgerald, A, Hersey, P, Jakrot, V, Johansson, P, Kakavand, H, Kefford, R, Lau, L, Long, G, Pickett, H, Pritchard, A, Pupo, G, Saw, R, Schramm, S, Shang, C, Shang, P, Spillane, A, Stretch, J, Tembe, V, Thompson, J, Vilain, R, Wilmott, J, Yang, J, Hayward, N, Mann, G, Scolyer, R, Bartlett, J, Bavi, P, Chadwick, D, Chan-Seng-Yue, M, Cleary, S, Connor, A, Czajka, K, Denroche, R, Dhani, N, Eagles, J, Gallinger, S, Grant, R, Hedley, D, Hollingsworth, M, Jang, G, Johns, J, Kalimuthu, S, Liang, S, Lungu, I, Luo, X, Mbabaali, F, Mcpherson, T, Miller, J, Moore, M, Notta, F, Pasternack, D, Petersen, G, Roehrl, M, Sam, M, Selander, I, Serra, S, Shahabi, S, Thayer, S, Timms, L, Wilson, G, Wilson, J, Wouters, B, Beck, T, Bhandari, V, Collins, C, Fleshner, N, Fox, N, Fraser, M, Heisler, L, Lalonde, E, Livingstone, J, Meng, A, Sabelnykova, V, Shiah, Y, Van der Kwast, T, Bristow, R, Ding, S, Fan, D, Li, L, Nie, Y, Xiao, X, Xing, R, Yang, S, Yu, Y, Zhou, Y, Banks, R, Bourque, G, Brennan, P, Letourneau, L, Riazalhosseini, Y, Scelo, G, Vasudev, N, Viksna, J, Lathrop, M, Tost, J, Ahn, S, Aparicio, S, Arnould, L, Aure, M, Bhosle, S, Birney, E, Borg, A, Boyault, S, Brinkman, A, Brock, J, Broeks, A, Borresen-Dale, A, Caldas, C, Chin, S, Davies, H, Desmedt, C, Dirix, L, Dronov, S, Ehinger, A, Eyfjord, J, Fatima, A, Foekens, J, Futreal, P, Garred, O, Giri, D, Glodzik, D, Grabau, D, Hilmarsdottir, H, Hooijer, G, Jacquemier, J, Jang, S, Jonasson, J, Jonkers, J, King, T, Knappskog, S, Kong, G, Krishnamurthy, S, Lakhani, S, Langerod, A, Larsimont, D, Lee, H, Lee, M, Lingjaerde, O, Macgrogan, G, Martens, J, O'Meara, S, Pauporte, I, Pinder, S, Pivot, X, Provenzano, E, Purdie, C, Ramakrishna, M, Ramakrishnan, K, Reis-Filho, J, Richardson, A, Ringner, M, Rodriguez, J, Rodriguez-Gonzalez, F, Romieu, G, Salgado, R, Sauer, T, Shepherd, R, Sieuwerts, A, Simpson, P, Smid, M, Sotiriou, C, Span, P, Stefansson, O, Stenhouse, A, Stunnenberg, H, Sweep, F, Tan, B, Thomas, G, Thompson, A, Tommasi, S, Treilleux, I, Tutt, A, Ueno, N, Van Laere, S, Van den Eynden, G, Vermeulen, P, Viari, A, Vincent-Salomon, A, Wong, B, Yates, L, Zou, X, van Deurzen, C, van de Vijver, M, van't Veer, L, Ammerpohl, O, Aukema, S, Bergmann, A, Bernhart, S, Borkhardt, A, Borst, C, Burkhardt, B, Claviez, A, Goebler, M, Haake, A, Haas, S, Hansmann, M, Hoell, J, Hummel, M, Karsch, D, Klapper, W, Kneba, M, Kreuz, M, Kube, D, Kuppers, R, Lenze, D, Loeffler, M, Lopez, C, Mantovani-Loffler, L, Moller, P, Ott, G, Radlwimmer, B, Richter, J, Rohde, M, Rosenstiel, P, Rosenwald, A, Schilhabel, M, Schreiber, S, Stadler, P, Staib, P, Stilgenbauer, S, Sungalee, S, Szczepanowski, M, Toprak, U, Trumper, L, Wagener, R, Zenz, T, Hovestadt, V, von Kalle, C, Kool, M, Korshunov, A, Landgraf, P, Lehrach, H, Northcott, P, Pfister, S, Reifenberger, G, Warnatz, H, Wolf, S, Yaspo, M, Assenov, Y, Gerhauser, C, Minner, S, Schlomm, T, Simon, R, Sauter, G, Sultmann, H, Biswas, N, Maitra, A, Majumder, P, Sarin, R, Barbi, S, Bonizzato, G, Cantu, C, Dei Tos, A, Fassan, M, Grimaldi, S, Luchini, C, Malleo, G, Marchegiani, G, Milella, M, Paiella, S, Pea, A, Pederzoli, P, Ruzzenente, A, Salvia, R, Sperandio, N, Arai, Y, Hama, N, Hiraoka, N, Hosoda, F, Nakamura, H, Ojima, H, Okusaka, T, Totoki, Y, Urushidate, T, Fukayama, M, Ishikawa, S, Katai, H, Katoh, H, Komura, D, Rokutan, H, Saito-Adachi, M, Suzuki, A, Taniguchi, H, Tatsuno, K, Ushiku, T, Yachida, S, Yamamoto, S, Aikata, H, Arihiro, K, Ariizumi, S, Chayama, K, Furuta, M, Gotoh, K, Hayami, S, Hirano, S, Kawakami, Y, Maejima, K, Nakamura, T, Nakano, K, Ohdan, H, Sasaki-Oku, A, Tanaka, H, Ueno, M, Yamamoto, M, Yamaue, H, Choo, S, Cutcutache, I, Khuntikeo, N, Ong, C, Pairojkul, C, Popescu, I, Ahn, K, Aymerich, M, Lopez-Guillermo, A, Lopez-Otin, C, Puente, X, Campo, E, Amary, F, Baumhoer, D, Behjati, S, Bjerkehagen, B, Myklebost, O, Pillay, N, Tarpey, P, Tirabosco, R, Zaikova, O, Flanagan, A, Boultwood, J, Bowen, D, Cazzola, M, Green, A, Hellstrom-Lindberg, E, Malcovati, L, Nangalia, J, Papaemmanuil, E, Vyas, P, Ang, Y, Barr, H, Beardsmore, D, Eldridge, M, Gossage, J, Grehan, N, Hanna, G, Hayes, S, Hupp, T, Khoo, D, Lagergren, J, Lovat, L, Macrae, S, O'Donovan, M, O'Neill, J, Parsons, S, Preston, S, Puig, S, Roques, T, Sanders, G, Sothi, S, Tavare, S, Tucker, O, Turkington, R, Underwood, T, Welch, I, Fitzgerald, R, Berney, D, De Bono, J, Cahill, D, Camacho, N, Dennis, N, Dudderidge, T, Edwards, S, Fisher, C, Foster, C, Ghori, M, Gill, P, Gnanapragasam, V, Gundem, G, Hamdy, F, Hawkins, S, Hazell, S, Howat, W, Isaacs, W, Karaszi, K, Kay, J, Khoo, V, Kote-Jarai, Z, Kremeyer, B, Kumar, P, Lambert, A, Leongamornlert, D, Livni, N, Luxton, H, Marsden, L, Massie, C, Matthews, L, Mayer, E, Mcdermott, U, Merson, S, Neal, D, Nicol, D, Ogden, C, Rowe, E, Shah, N, Thomas, S, Verrill, C, Visakorpi, T, Warren, A, Whitaker, H, Zhang, H, van As, N, Eeles, R, Abeshouse, A, Agrawal, N, Akbani, R, Al-Ahmadie, H, Albert, M, Aldape, K, Ally, A, Appelbaum, E, Armenia, J, Asa, S, Auman, J, Balasundaram, M, Balu, S, Barnholtz-Sloan, J, Bathe, O, Baylin, S, Benz, C, Berchuck, A, Berrios, M, Bigner, D, Birrer, M, Bodenheimer, T, Boice, L, Bootwalla, M, Bosenberg, M, Bowlby, R, Boyd, J, Broaddus, R, Brock, M, Brooks, D, Bullman, S, Caesar-Johnson, S, Carey, T, Carlsen, R, Cerfolio, R, Chandan, V, Chen, H, Cherniack, A, Chien, J, Cho, J, Chuah, E, Cibulskis, C, Cope, L, Cordes, M, Curley, E, Czerniak, B, Danilova, L, Davis, I, Defreitas, T, Demchok, J, Dhalla, N, Dhir, R, Doddapaneni, H, El-Naggar, A, Felau, I, Ferguson, M, Finocchiaro, G, Fong, K, Frazer, S, Friedman, W, Fronick, C, Fulton, L, Gabriel, S, Gao, J, Gehlenborg, N, Gershenwald, J, Ghossein, R, Giama, N, Gibbs, R, Gomez, C, Govindan, R, Hayes, D, Hegde, A, Heiman, D, Heins, Z, Hepperla, A, Holbrook, A, Holt, R, Hoyle, A, Hruban, R, Hu, J, Huntsman, D, Huse, J, Iacobuzio-Donahue, C, Ittmann, M, Jayaseelan, J, Jefferys, S, Jones, C, Jones, S, Juhl, H, Kang, K, Karlan, B, Kasaian, K, Kebebew, E, Korchina, V, Kundra, R, Lai, P, Lander, E, Le, X, Levine, D, Lewis, L, Ley, T, Li, H, Lin, P, Linehan, W, Lype, L, Ma, Y, Maglinte, D, Mardis, E, Marks, J, Marra, M, Matthew, T, Mayo, M, Mccune, K, Meier, S, Meng, S, Mieczkowski, P, Mikkelsen, T, Miller, C, Mills, G, Moore, R, Morrison, C, Mose, L, Moser, C, Mungall, A, Mungall, K, Mutch, D, Muzny, D, Myers, J, Newton, Y, Noble, M, O'Donnell, P, O'Neill, B, Ochoa, A, Parker, J, Pass, H, Pastore, A, Pennell, N, Perou, C, Petrelli, N, Potapova, O, Rader, J, Ramalingam, S, Rathmell, W, Reuter, V, Reynolds, S, Ringel, M, Roach, J, Roberts, L, Sadeghi, S, Saller, C, Sanchez-Vega, F, Schadendorf, D, Schein, J, Schmidt, H, Schultz, N, Seethala, R, Senbabaoglu, Y, Shelton, T, Shi, Y, Shih, J, Shmulevich, I, Shriver, C, Signoretti, S, Simons, J, Singer, S, Sipahimalani, P, Skelly, T, Smith-McCune, K, Socci, N, Soloway, M, Sood, A, Tam, A, Tan, D, Tarnuzzer, R, Thiessen, N, Thompson, R, Thorne, L, Tsao, M, Umbricht, C, Van Den Berg, D, Van Meir, E, Veluvolu, U, Voet, D, Wang, L, Weinberger, P, Weisenberger, D, Wigle, D, Wilkerson, M, Wilson, R, Winterhoff, B, Wiznerowicz, M, Wong, T, Wong, W, Xi, L, Yau, C, Consortium, ICGC/TCGA Pan-Cancer Analysis of Whole Genomes, Demeulemeester, Jonas, Desmedt, Christine, Van Loo, Peter, Barcelona Supercomputing Center, Imperial College Healthcare NHS Trust- BRC Funding, Cancer Research UK, Basic (bio-) Medical Sciences, and Laboratory for Medical and Molecular Oncology
- Subjects
Male ,tert promoter mutations ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,DNA Mutational Analysis ,Normal tissue ,systematic analysis ,Germline ,Transcriptome ,0302 clinical medicine ,Aetiology ,Càncer ,Cellular Senescence ,Cancer ,0303 health sciences ,dna-damage ,Massive parallel sequencing ,Pan cancer ,REARRANGEMENTS ,High-Throughput Nucleotide Sequencing ,Genomics ,Sciences bio-médicales et agricoles ,Telomere ,COMPREHENSIVE ,3. Good health ,TERT PROMOTER MUTATIONS ,signatures ,030220 oncology & carcinogenesis ,Science & Technology - Other Topics ,Erfðarannsóknir ,Human ,Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC] ,Evolution ,RNA Splicing ,Article ,Evolution, Molecular ,Structural variation ,RC0254 ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Genetic ,genomics ,SYSTEMATIC ANALYSIS ,Genetics ,Genomics--Databases ,Humans ,Genetic Testing ,Molecular Biology ,SIGNATURES ,Whole genome sequencing ,1000 Multidisciplinary ,Chromothripsis ,Science & Technology ,RC0254 Neoplasms. Tumors. Oncology (including Cancer) ,Information Dissemination ,ResearchInstitutes_Networks_Beacons/mcrc ,Prevention ,Biology and Life Sciences ,Molecular ,Oncogenes ,Cloud Computing ,medicine.disease ,Genòmica ,Compute clouds ,Mutation ,570 Life sciences ,biology ,COMPREHENSIVE CHARACTERIZATION ,Genètica ,Whole Genome Sequencing--methods ,Background information ,Genetic / genetics ,Genome ,Germ-Line Mutation / genetics ,Human / genetics ,ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium ,Medizin ,Whole-genome ,Genome mapping ,Neoplasms ,2.1 Biological and endogenous factors ,Promoter Regions, Genetic ,Càncer -- Aspectes genètics ,Telomerase ,Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17] ,Multidisciplinary ,Manchester Cancer Research Centre ,genomics, cancer, profiling ,3rd-DAS ,10124 Institute of Molecular Life Sciences ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Multidisciplinary Sciences ,Parallel sequencing ,Female ,profiling ,Medical Genetics ,Engineering sciences. Technology ,Biotechnology ,General Science & Technology ,The Cancer Genome Atlas ,610 Medicine & health ,Computational biology ,QH426 Genetics ,Biology ,Consortium of the International Cancer Genome Consortium ,Promoter Regions ,Germline mutation ,Pan-cancer analysis ,Krabbameinsrannsóknir ,medicine ,cancer ,ddc:610 ,QH426 ,Germ-Line Mutation ,Medicinsk genetik ,Krabbamein ,030304 developmental biology ,Cell Proliferation ,LANDSCAPE ,Genome, Human ,comprehensive characterization ,Pan-cancer analysis of whole genomes ,Point mutation ,Human Genome ,Reproducibility of Results ,SOMATIC MUTATIONS ,EVOLUTION ,Cancer, sequencing, Chromothripsis, telomere ,DNA-DAMAGE ,Mutagenesis ,PATTERNS ,3111 Biomedicine ,CHARACTERIZATION - Abstract
Publisher's version (útgefin grein), Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1,2,3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10,11,12,13,14,15,16,17,18., Competing interests Gad Getz receives research funds from IBM and Pharmacyclics and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig, MSMuTect, MSMutSig and POLYSOLVER. Hikmat Al-Ahmadie is consultant for AstraZeneca and Bristol-Myers Squibb. Samuel Aparicio is a founder and shareholder of Contextual Genomics. Pratiti Bandopadhayay receives grant funding from Novartis for an unrelated project. Rameen Beroukhim owns equity in Ampressa Therapeutics. Andrew Biankin receives grant funding from Celgene, AstraZeneca and is a consultant for or on advisory boards of AstraZeneca, Celgene, Elstar Therapeutics, Clovis Oncology and Roche. Ewan Birney is a consultant for Oxford Nanopore, Dovetail and GSK. Marcus Bosenberg is a consultant for Eli Lilly. Atul Butte is a cofounder of and consultant for Personalis, NuMedii, a consultant for Samsung, Geisinger Health, Mango Tree Corporation, Regenstrief Institute and in the recent past a consultant for 10x Genomics and Helix, a shareholder in Personalis, a minor shareholder in Apple, Twitter, Facebook, Google, Microsoft, Sarepta, 10x Genomics, Amazon, Biogen, CVS, Illumina, Snap and Sutro and has received honoraria and travel reimbursement for invited talks from Genentech, Roche, Pfizer, Optum, AbbVie and many academic institutions and health systems. Carlos Caldas has served on the Scientific Advisory Board of Illumina. Lorraine Chantrill acted on an advisory board for AMGEN Australia in the past 2 years. Andrew D. Cherniack receives research funding from Bayer. Helen Davies is an inventor on a number of patent applications that encompass the use of mutational signatures. Francisco De La Vega was employed at Annai Systems during part of the project. Ronny Drapkin serves on the scientific advisory board of Repare Therapeutics and Siamab Therapeutics. Rosalind Eeles has received an honorarium for the GU-ASCO meeting in San Francisco in January 2016 as a speaker, a honorarium and support from Janssen for the RMH FR meeting in November 2017 as a speaker (title: genetics and prostate cancer), a honorarium for an University of Chicago invited talk in May 2018 as speaker and an educational honorarium paid by Bayer & Ipsen to attend GU Connect ‘Treatment sequencing for mCRPC patients within the changing landscape of mHSPC’ at a venue at ESMO, Barcelona, on 28 September 2019. Paul Flicek is a member of the scientific advisory boards of Fabric Genomics and Eagle Genomics. Ronald Ghossein is a consultant for Veracyte. Dominik Glodzik is an inventor on a number of patent applications that encompass the use of mutational signatures. Eoghan Harrington is a full-time employee of Oxford Nanopore Technologies and is a stock holder. Yann Joly is responsible for the Data Access Compliance Office (DACO) of ICGC 2009-2018. Sissel Juul is a full-time employee of Oxford Nanopore Technologies and is a stock holder. Vincent Khoo has received personal fees and non-financial support from Accuray, Astellas, Bayer, Boston Scientific and Janssen. Stian Knappskog is a coprincipal investigator on a clinical trial that receives research funding from AstraZeneca and Pfizer. Ignaty Leshchiner is a consultant for PACT Pharma. Carlos López-Otín has ownership interest (including stock and patents) in DREAMgenics. Matthew Meyerson is a scientific advisory board chair of, and consultant for, OrigiMed, has obtained research funding from Bayer and Ono Pharma and receives patent royalties from LabCorp. Serena Nik-Zainal is an inventor on a number of patent applications that encompass the use of mutational signatures. Nathan Pennell has done consulting work with Merck, Astrazeneca, Eli Lilly and Bristol-Myers Squibb. Xose S. Puente has ownership interest (including stock and patents in DREAMgenics. Benjamin J. Raphael is a consultant for and has ownership interest (including stock and patents) in Medley Genomics. Jorge Reis-Filho is a consultant for Goldman Sachs and REPARE Therapeutics, member of the scientific advisory board of Volition RX and Paige.AI and an ad hoc member of the scientific advisory board of Ventana Medical Systems, Roche Tissue Diagnostics, InVicro, Roche, Genentech and Novartis. Lewis R. Roberts has received grant support from ARIAD Pharmaceuticals, Bayer, BTG International, Exact Sciences, Gilead Sciences, Glycotest, RedHill Biopharma, Target PharmaSolutions and Wako Diagnostics and has provided advisory services to Bayer, Exact Sciences, Gilead Sciences, GRAIL, QED Therapeutics and TAVEC Pharmaceuticals. Richard A. Scolyer has received fees for professional services from Merck Sharp & Dohme, GlaxoSmithKline Australia, Bristol-Myers Squibb, Dermpedia, Novartis Pharmaceuticals Australia, Myriad, NeraCare GmbH and Amgen. Tal Shmaya is employed at Annai Systems. Reiner Siebert has received speaker honoraria from Roche and AstraZeneca. Sabina Signoretti is a consultant for Bristol-Myers Squibb, AstraZeneca, Merck, AACR and NCI and has received funding from Bristol-Myers Squibb, AstraZeneca, Exelixis and royalties from Biogenex. Jared Simpson has received research funding and travel support from Oxford Nanopore Technologies. Anil K. Sood is a consultant for Merck and Kiyatec, has received research funding from M-Trap and is a shareholder in BioPath. Simon Tavaré is on the scientific advisory board of Ipsen and a consultant for Kallyope. John F. Thompson has received honoraria and travel support for attending advisory board meetings of GlaxoSmithKline and Provectus and has received honoraria for participation in advisory boards for MSD Australia and BMS Australia. Daniel Turner is a full-time employee of Oxford Nanopore Technologies and is a stock holder. Naveen Vasudev has received speaker honoraria and/or consultancy fees from Bristol-Myers Squibb, Pfizer, EUSA pharma, MSD and Novartis. Jeremiah A. Wala is a consultant for Nference. Daniel J. Weisenberger is a consultant for Zymo Research. Dai-Ying Wu is employed at Annai Systems. Cheng-Zhong Zhang is a cofounder and equity holder of Pillar Biosciences, a for-profit company that specializes in the development of targeted sequencing assays. The other authors declare no competing interests.
- Published
- 2020
- Full Text
- View/download PDF
3. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
- Author
-
Wong, GL-H, Wong, VW-S, Thompson, A, Jia, J, Hou, J, Lesmana, CRA, Susilo, A, Tanaka, Y, Chan, W-K, Gane, E, Ong-Go, AK, Lim, S-G, Ahn, SH, Yu, M-L, Piratvisuth, T, Chan, HL-Y, Wong, GL-H, Wong, VW-S, Thompson, A, Jia, J, Hou, J, Lesmana, CRA, Susilo, A, Tanaka, Y, Chan, W-K, Gane, E, Ong-Go, AK, Lim, S-G, Ahn, SH, Yu, M-L, Piratvisuth, T, and Chan, HL-Y
- Abstract
The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or both. The clinical implications of liver derangement might be variable in different clinical scenarios. With growing evidence of its clinical significance, it would be clinically helpful to provide practice recommendations for various common clinical scenarios of liver derangement during the COVID-19 pandemic. The Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic was formed to systematically review the literature with special focus on the clinical management of patients who have been or who are at risk of developing liver derangement during this pandemic. Clinical scenarios covering the use of pharmacological treatment for COVID-19 in the case of liver derangement, and assessment and management of patients with chronic hepatitis B or hepatitis C, non-alcoholic fatty liver disease, liver cirrhosis, and liver transplantation during the pandemic are discussed.
- Published
- 2020
4. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B
- Author
-
Chemin, I, Wei, L, Wedemeyer, H, Liaw, Y-F, Chan, HL-Y, Piratvisuth, T, Marcellin, P, Jia, J, Tan, D, Chow, W-C, Brunetto, MR, Diago, M, Gurel, S, Morozov, V, He, H, Zhu, Y, Wat, C, Surujbally, B, Thompson, AJ, Chemin, I, Wei, L, Wedemeyer, H, Liaw, Y-F, Chan, HL-Y, Piratvisuth, T, Marcellin, P, Jia, J, Tan, D, Chow, W-C, Brunetto, MR, Diago, M, Gurel, S, Morozov, V, He, H, Zhu, Y, Wat, C, Surujbally, B, and Thompson, AJ
- Abstract
BACKGROUND & AIMS: It has yet to be firmly established whether host IFNL3 (IL28B) genotype influences interferon responsiveness in patients with chronic hepatitis B. We investigated associations between single-nucleotide polymorphisms (SNPs) in the IFNL3 region and response to peginterferon alfa-2a in 701 patients enrolled in three large, randomized, international studies. METHODS: Responses were defined as hepatitis B surface antigen (HBsAg) loss and/or hepatitis B e antigen (HBeAg) seroconversion plus hepatitis B virus (HBV) DNA <2000 IU/ml in HBeAg-positive patients, and HBsAg loss and/or HBV DNA <2000 IU/ml in HBeAg-negative patients (24 weeks after end of treatment). Associations between treatment response and the number of copies of the poor-response allele at three SNPs (rs8099917, rs12980275, rs12979860) were explored with logistic regression models in Asian and white patients. RESULTS: The HBeAg-positive and -negative populations comprised 465 (92% Asian, 50% HBV genotype C) and 236 (79% Asian, 41% HBV genotype C) patients, respectively, and had respective response rates of 26% and 47%. The IFNL3 genotype was strongly associated with ethnicity. There was no association between IFNL3 genotype and treatment response in HBeAg-positive or -negative patients. Independent predictors of treatment response were: sex, HBV DNA level and alanine aminotransferase level in HBeAg-positive Asian patients; age in HBeAg-negative Asian patients; and HBV DNA in HBeAg-negative white patients. CONCLUSIONS: This is the largest analysis to date of associations between IFNL3 genotype and peginterferon response in patients with chronic hepatitis B. The data suggest that IFNL3 polymorphism is not a major determinant of the response to peginterferon alfa-2a in either HBeAg-positive or HBeAg-negative patients.
- Published
- 2018
5. Einige Untersuchungen über Strömungs-doppelbrechung
- Author
-
Snellman, O. and Björnst»hl, Y.
- Published
- 1941
- Full Text
- View/download PDF
6. Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report
- Author
-
Chan, HL-Y, Thompson, A, Martinot-Peignoux, M, Piratvisuth, T, Cornberg, M, Brunetto, MR, Tillmann, HL, Kao, J-H, Jia, J-D, Wedemeyer, H, Locarnini, S, Janssen, HLA, Marcellin, P, Chan, HL-Y, Thompson, A, Martinot-Peignoux, M, Piratvisuth, T, Cornberg, M, Brunetto, MR, Tillmann, HL, Kao, J-H, Jia, J-D, Wedemeyer, H, Locarnini, S, Janssen, HLA, and Marcellin, P
- Abstract
Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome. The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B. HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies. Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients. Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients. The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment. On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders. The optimal on-treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a <2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg-negative patients with genotype D HBV infection. A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term. There are early reports among Asian patients that an HBsAg level of <100IU/ml might predict lower risk of relapse after stopping NA treatment. In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.
- Published
- 2011
7. Nonequilibrium theory of dirty, current-carrying superconductors: phase-slip oscillators in narrow filaments near T c
- Author
-
Watts-Tobin, R. J., primary, Kr�henb�hl, Y., additional, and Kramer, L., additional
- Published
- 1981
- Full Text
- View/download PDF
8. Theory of phase-slip processes in thin and dirty current-carrying superconducting wires: Deviations from local equilibrium
- Author
-
Kr�henb�hl, Y., primary
- Published
- 1983
- Full Text
- View/download PDF
9. Microscopic theory of the current-voltage relationship across a normal-superconducting interface
- Author
-
Kr�henb�hl, Y., primary and Watts-Tobin, R. J., additional
- Published
- 1979
- Full Text
- View/download PDF
10. �ber ein einfaches Couette-Viskosimeter mit Thermostateinrichtung sowie einige Versuche, mittels dessen die Einwirkung eines elektrischen Feldes auf die Viskosit�t anisotroper Fl�ssigkeiten zu untersuchen
- Author
-
Bj�rnst�hl, Y., primary and Snellman, O., additional
- Published
- 1939
- Full Text
- View/download PDF
11. Delayed-onset pineal abscess following transsphenoidal surgery for pituitary adenoma: a case report
- Author
-
HL, Y
- Published
- 2003
12. Predictive Factors of Intra-articular Corticosteroid Injections With Ultrasound-Guided Posterior Capsule Approach for Patients With Primary Adhesive Capsulitis.
- Author
-
Lin CL, Lee YH, Chen YW, Liao CD, and Huang SW
- Subjects
- Humans, Retrospective Studies, Adrenal Cortex Hormones therapeutic use, Pain complications, Injections, Intra-Articular adverse effects, Ultrasonography, Interventional, Range of Motion, Articular physiology, Shoulder Pain diagnostic imaging, Shoulder Pain drug therapy, Shoulder Pain etiology, Treatment Outcome, Bursitis diagnostic imaging, Bursitis drug therapy, Bursitis complications, Shoulder Joint diagnostic imaging, Diabetes Mellitus
- Abstract
Background: Adhesive capsulitis affects the shoulder joint, causing pain and limiting motion. In clinical practice, the effectiveness of injections varies, and the factors influencing their success remain unclear. This study investigates the predictors of effective corticosteroid injections in patients with primary adhesive capsulitis., Design: This retrospective study enrolled adhesive capsulitis patients older than 35 yrs who received intra-articular corticosteroid injections. The response was determined based on patients' pain and range of motion 3 mos after the injection. Demographic data, medical comorbidities, and radiographic parameters (critical shoulder angle and acromial index) were compared between the effective and noneffective groups. Receiver operating characteristic curves and logistic regression were used to identify the predictors of injection effectiveness., Results: This study included 325 patients with primary adhesive capsulitis, who were divided into responder (189 patients, 58.2%) and nonresponder (136 patients, 41.8%) groups. The receiver operating characteristic curve revealed that the acromial index score indicated favorable discrimination for predicting a poor response to injections, whereas the critical shoulder angle score did not. Logistic regression revealed that the pain period, diabetes mellitus, and acromial index are predictors of nonresponders to injections., Conclusions: Long pain duration, the presence of diabetes mellitus, and an acromial index score greater than 0.711 were predictors of nonresponse to corticosteroid injections for primary adhesive capsulitis patients., Competing Interests: Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Comparison Clinical Effects of Hypertonic Dextrose and Steroid Injections on Chronic Subacromial Bursitis: A Double-Blind Randomized Controlled Trial.
- Author
-
Lin LC, Lee YH, Chen YW, Hsu TH, Vitoonpong T, Liou TH, and Huang SW
- Subjects
- Humans, Treatment Outcome, Injections, Intra-Articular, Steroids therapeutic use, Chronic Disease, Glucose, Shoulder Pain drug therapy, Bursitis drug therapy
- Abstract
Objective: The aim of the study is to determine and compare the treatment efficacy of subacromial steroid injections and dextrose prolotherapy for chronic subacromial bursitis patients., Design: Fifty-four patients with chronic subacromial bursitis were enrolled in this double-blind randomized controlled trial. Shoulder Pain and Disability Index and visual analog scale were the primary outcomes., Results: The steroid group ( n = 26) exhibited significant visual analog scale score improvements comparing with baseline at weeks 2, 6, and 12; the dextrose prolotherapy group ( n = 28) exhibited visual analog scale score improvements at weeks 6 and 12. The steroid group displayed significant Shoulder Pain and Disability Index score improvements compared with baseline at weeks 2, 6, and 12; the dextrose prolotherapy group exhibited significant score decreases at weeks 2 and 6. Compared with the dextrose prolotherapy group, the steroid group demonstrated significantly greater decreases in visual analog scale scores at weeks 2 and 6; the steroid group showed significantly greater decreases in Shoulder Pain and Disability Index scores at weeks 2, 6, and 12., Conclusions: Both hypertonic dextrose prolotherapy and steroid injections can provide short-term improvements of pain and disability among chronic subacromial bursitis patients. Moreover, steroid injections showed better effectiveness than hypertonic dextrose prolotherapy in ameliorating pain and improving function., Competing Interests: Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Prediction of fluid responsiveness using lung recruitment manoeuvre in paediatric patients receiving lung-protective ventilation: A prospective observational study.
- Author
-
Kim EH, Lee JH, Jang YE, Ji SH, Kim HS, Cho SA, and Kim JT
- Subjects
- Blood Pressure, Child, Crystalloid Solutions, Hemodynamics, Humans, Infant, Newborn, Lung, ROC Curve, Stroke Volume, Tidal Volume, Fluid Therapy, Respiration, Artificial
- Abstract
Background: Pressure-based dynamic variables are poor predictors of fluid responsiveness in children, and their predictability is expected to reduce further during lung-protective ventilation with a low tidal volume., Objective: We hypothesised that lung recruitment manoeuvre (LRM)-induced changes in dynamic variables improve their ability to predict fluid responsiveness in children., Design: Prospective observational study., Setting: Tertiary care children's hospital, single-centre study performed from June 2017 to May 2019., Patients: We included patients less than 7 years of age undergoing cardiac surgery. Neonates and patients with pulmonary hypertension, significant dysrhythmia, ventricular ejection fraction of less than 30% or pulmonary disease were excluded., Intervention: All patients were provided with lung-protective volume-controlled ventilation (tidal volume 6 ml kg-1, positive end-expiratory pressure 6 cmH2O). A LRM was applied with a continuous inspiratory pressure of 25 cmH2O for 20 s., Main Outcome Measure: The ability of dynamic variables to predict fluid responsiveness was evaluated by the area under the receiver operating characteristic curve [area under the curve (AUC)]. Fluid responsiveness was defined as an increase in the cardiac index by more than 15% with crystalloid administration (10 ml kg-1)., Results: Thirty patients were included in the final analysis, of whom 19 were responders. The baseline pleth variability index (PVI) (AUC 0.794, 95% confidence interval 0.608 to 0.919, P < 0.001) and LRM-induced PVI (AUC 0.711, 95% confidence interval 0.517 to 0.861, P = 0.026) could predict fluid responsiveness. The respiratory variation of pulse oximetry photoplethysmographic waveform and pulse pressure variation did not predict fluid responsiveness regardless of the LRM., Conclusion: The PVI is effective in predicting fluid responsiveness in paediatric patients with lung-protective ventilation regardless of a LRM. However, the LRM did not improve the ability of the other dynamic variables to predict fluid responsiveness in these patients., Clinical Trial Registration: www.clinicaltrials.gov identifier: NCT03184961., (Copyright © 2020 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.)
- Published
- 2021
- Full Text
- View/download PDF
15. Motivators for and Barriers to Exercise Rehabilitation in Hemodialysis Centers: A Multicenter Cross-Sectional Survey.
- Author
-
Wang XX, Lin ZH, Wang Y, Xu MC, Kang ZM, Zeng W, and Ma YC
- Subjects
- Adult, Aged, Aged, 80 and over, Ambulatory Care Facilities, China, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Motivation, Surveys and Questionnaires, Attitude to Health, Exercise Therapy psychology, Renal Dialysis
- Abstract
Objectives: The aim of the study was to explore motivators for and barriers to exercise rehabilitation in hemodialysis patients and the barriers perceived by the hemodialysis center staff., Design: A cross-sectional study was performed in five hemodialysis centers using patient questionnaires designed for this study to evaluate the motivators for and barriers to exercise rehabilitation. Questionnaires were not yet validated., Results: Of the 471 recruited patients, 63.3% were willing to participant in exercise rehabilitation. The greatest motivators included improving quality of life (98.0%) and wanting to be healthier (98.0%). Perceived barriers included discomfort (59.0%), concerns regarding safety (36.7%), and disinterest (27.0%). Among these, unwillingness, disinterest, and having peripheral arterial disease were independent risk factors of lack of participation in exercise rehabilitation. The most common perceived barriers among the 90 employees that participated were lack of professional guidance and advice from rehabilitation therapists (93.1%), lack of exercise rehabilitation knowledge (86.2%), and lack of special exercise equipment (86.2%)., Conclusions: Most patients were willing to exercise to improve their health and quality of life. Barriers to exercise rehabilitation included patient and staff factors. It is essential to establish a rehabilitation team within dialysis centers, including general staff and rehabilitation therapists. These centers require improved rehabilitation policies and access to specialized rehabilitation equipment.
- Published
- 2020
- Full Text
- View/download PDF
16. Evaluation of preoperative oral carbohydrate administration on insulin resistance in off-pump coronary artery bypass patients: A randomised trial.
- Author
-
Lee B, Soh S, Shim JK, Kim HY, Lee H, and Kwak YL
- Subjects
- Administration, Oral, Aged, Coronary Artery Bypass, Off-Pump adverse effects, Fatty Acids, Nonesterified blood, Female, Humans, Male, Middle Aged, Prospective Studies, Coronary Artery Bypass, Off-Pump trends, Dietary Carbohydrates administration & dosage, Insulin Resistance physiology, Postoperative Complications blood, Postoperative Complications prevention & control, Preoperative Care methods
- Abstract
Background: In fasting cardiac surgery patients, preoperative carbohydrate (CHO) drink intake attenuated insulin resistance and improved cardiac metabolism, although its beneficial effects were not evident after cardiac surgery possibly due to cardiopulmonary bypass-related extreme systemic inflammation., Objective: We aimed to evaluate whether preoperative CHO intake affected insulin resistance and free-fatty acid (FFA) concentrations in off-pump coronary revascularisation., Design: A randomised controlled trial., Setting: Primary care in a university hospital in Korea from January 2015 to July 2016., Patients: Sixty patients who underwent elective multi-vessel off-pump coronary revascularisation were randomised into two groups. Three patients were excluded from analysis and 57 patients completed study., Intervention: The CHO group received oral CHO (400 ml) the prior evening and 2 to 3 h before surgery, and the control group was fasted from food and water according to standard protocol., Main Outcome Measures: Insulin resistance was assessed twice, after anaesthetic induction and after surgery via short insulin tolerance test. FFA, C-reactive protein and creatine kinase-myocardial band concentrations were determined serially for 48 h after surgery., Results: Insulin sensitivity was greater (P = 0.002) and plasma FFA concentrations were lower (P = 0.001) after anaesthetic induction in the CHO group compared with the Control group, although there were no intergroup differences after surgery. The postoperative peak creatine kinase-myocardial band concentration was significantly lower in the CHO group compared with the Control group [8.8 (5.4 to 18.2) vs. 6.4 (3.5 to 9.7) ng ml, P = 0.031]., Conclusion: A preoperative CHO supplement significantly reduced insulin resistance and FFA concentrations compared with fasting at the beginning of the surgery, but these benefits were lost after off-pump coronary revascularisation. Despite their transient nature, these beneficial effects resulted in less myocardial injury, mandating further studies focused on the impact of preoperative CHO on myocardial ischaemia and cardiac function after coronary revascularisation., Trial Registration: Clinicaltrials.gov identifier: NCT 02330263.
- Published
- 2017
- Full Text
- View/download PDF
17. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
- Author
-
Chuah SK, Liang CM, Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, and Tai WC
- Subjects
- Adult, Aged, Amoxicillin administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Esomeprazole administration & dosage, Female, Humans, Intention to Treat Analysis, Male, Metronidazole administration & dosage, Middle Aged, Prospective Studies, Proton Pump Inhibitors administration & dosage, Treatment Outcome, Anti-Infective Agents administration & dosage, Helicobacter Infections drug therapy, Helicobacter pylori drug effects, Levofloxacin administration & dosage
- Abstract
Summary of Trial Design.Lengthy exposure to quinolone-containing triple therapy in Helicobacter pylori eradication leads to the development of drug resistance. Sequential therapy with a quinolone and metronidazole -containing regimen appears to be an effective treatment option. This randomized controlled trial aimed to compare the efficacy of 5-plus 5 days' levofloxacin and metronidazole-containing sequential therapy (EALM) with that of 10-day levofloxacin-containing triple therapy (EAL) in second-line H pylori eradication treatment.One hundred and sixty-four patients who had failed the H pylori eradication attempts using the standard triple therapy (proton pump inhibitor bid, clarithromycin 500 mg bid, amoxicillin 1 g bid × 7 days) were randomly assigned to either an EALM therapy group (n = 82; esomeprazole 40 mg bid and amoxicillin 1 g bid for 5 days, followed by esomeprazole 40 mg bid, levofloxacin 500 mg qd, and metronidazole 500 mg tid, for 5 days) or a 10-day EAL therapy group (n = 82; levofloxacin 500 mg qd, amoxicillin 1 g bid, and esomeprazole 40 mg bid). One patient was lost to follow-up in each group. Follow-up for H pylori status was performed 4 to 8 weeks later.Eradication rates for the EALM and EAL groups were 90.2% (74/82, 95% confidence interval [CI] = 83.7%-96.8%) and 80.5% (66/82, 95% CI = 71.7%-89.2%, P = 0.077) in the intention-to-treat analysis; and 91.4% (74/81, 95% CI = 85.1%-97.6%) and 81.5% (66/81, 95% CI = 72.8%-90.1%, P = 0.067) in the per-protocol analysis. The adverse events for the EALM and EAL groups were 23.5% versus 11.1%, P = 0.038 but were all very mild and were well tolerated except for 1 patient with poor compliance. The compliances were 98.8% and 100%, respectively, between the 2 groups. An antibiotic resistance to levofloxacin was the clinical factor influencing the efficacy of H. pylori eradication therapy in the EAL group, and dual resistance to levofloxacin and metronidazole in the EALM group.Levofloxacin and metronidazole-containing sequential therapy achieved a >90% eradication rate as a second-line H pylori therapy. Dual antibiotic resistance to levofloxacin and metronidazole was the clinical factor influencing the efficacy of H pylori eradication therapy in the sequential therapy (ClinicalTrials.gov number: NCT02596620).
- Published
- 2016
- Full Text
- View/download PDF
18. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
- Author
-
Hsieh YC, Hung CY, Li CH, Liao YC, Huang JL, Lin CH, and Wu TJ
- Subjects
- Aged, Comorbidity, Drug Prescriptions statistics & numerical data, Female, Follow-Up Studies, Humans, Hypertension drug therapy, Hypertension epidemiology, Incidence, Ischemic Attack, Transient epidemiology, Male, Middle Aged, Proportional Hazards Models, Protective Factors, Stroke epidemiology, Taiwan epidemiology, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Atrial Fibrillation epidemiology, Atrial Fibrillation prevention & control
- Abstract
Both angiotensin-receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) have protective effects against atrial fibrillation (AF). The differences between ARB and ACEI in their effects on the primary prevention of AF remain unclear. This study compared ARB and ACEI in combined antihypertensive medications for reducing the risk of AF in patients with hypertension, and determined which was better for AF prevention in a nationwide cohort study.Patients aged ≥55 years and with a history of hypertension were identified from Taiwan National Health Insurance Research Database. Medical records of 25,075 patients were obtained, and included 6205 who used ARB, 8034 who used ACEI, and 10,836 nonusers (no ARB or ACEI) in their antihypertensive regimen. Cox regression models were applied to estimate the hazard ratio (HR) for new-onset AF.During an average of 7.7 years' follow-up, 1619 patients developed new-onset AF. Both ARB (adjusted HR: 0.51, 95% CI 0.44-0.58, P < 0.001) and ACEI (adjusted HR: 0.53, 95% CI 0.47-0.59, P < 0.001) reduced the risk of AF compared to nonusers. Subgroup analysis showed that ARB and ACEI were equally effective in preventing new-onset AF regardless of age, gender, the presence of heart failure, diabetes, and vascular disease, except for those with prior stroke or transient ischemic attack (TIA). ARB prevents new-onset AF better than ACEI in patients with a history of stroke or TIA (log-rank P = 0.012).Both ARB and ACEI reduce new-onset AF in patients with hypertension. ARB prevents AF better than ACEI in patients with a history of prior stroke or TIA.
- Published
- 2016
- Full Text
- View/download PDF
19. The Explorative Analysis to Revise Fear Network Model for Panic Disorder: Functional Connectome Statistics.
- Author
-
Lai CH and Wu YT
- Subjects
- Adult, Female, Frontal Lobe physiopathology, Gyrus Cinguli physiopathology, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuroimaging, Occipital Lobe physiopathology, Panic Disorder diagnostic imaging, Parahippocampal Gyrus physiopathology, Brain physiopathology, Connectome, Fear physiology, Models, Neurological, Panic Disorder physiopathology
- Abstract
Functional connectome analysis in panic disorder (PDO) is a relatively new field for research. We tried to investigate the functional connectome alterations in PDO to re-examine the precision and role of fear network model for the pathophysiology of PDO.We enrolled 53 PDO patients and 54 controls with imaging data in this study. After preprocessing, we calculated the connectivity matrix of functional connectivity in whole brain for each subject. Then network-based statistics (The University of Melbourne and Melbourne Health, Australia) of connectome was used to perform group comparisons between patients and controls. The correlation between network measures of significant subnetwork and illness duration or severity of PDO was also performed.Within the 6 network models, only 1 network survived after multiple corrections. We found decreased functional connectivity in the edges between the following nodes: the left parahippocampal gyrus, bilateral precentral gyri, bilateral middle cingulate gyri, bilateral supramarginal gyri, bilateral calcarine fissures, and right lingual gyrus. The central hubs were the left parahippocampal gyrus and left precentral gyrus. The importance of limbic areas and connection with sensory and motor regions might shed light on the revision of fear network model for the pathophysiology of PDO.
- Published
- 2016
- Full Text
- View/download PDF
20. Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients.
- Author
-
Hsiao LT, Wang HY, Yang CF, Chiou TJ, Gau JP, Yu YB, Liu HL, Chang WC, Chen PM, Tzeng CH, Chan YJ, Yang MH, Liu JH, and Huang YH
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Haplotypes, Hepatitis B complications, Hepatitis B immunology, Humans, Interleukin-4 genetics, Lymphoma, Non-Hodgkin complications, Male, Middle Aged, Polymorphism, Single Nucleotide, Recurrence, Regression Analysis, Retrospective Studies, Seroconversion drug effects, Antineoplastic Agents adverse effects, Cytokines genetics, Hepatitis B chemically induced, Lymphoma, Non-Hodgkin drug therapy, Rituximab adverse effects
- Abstract
Hepatitis B virus (HBV) reactivation has been noted in HBV surface antigen (HBsAg)-seronegative patients with CD20 B-cell non-Hodgkin lymphoma (NHL) undergoing rituximab treatment. Clinically, hepatitis flares are usually associated with the reappearance of HBsAg (reverse seroconversion of HBsAg, HBV-RS). It is unclear whether human genetic factors are related to rituximab-associated HBV reactivation. Unvaccinated HBsAg-seronegative adults (n = 104) with CD20 NHL who had received rituximab-containing therapy without anti-HBV prophylaxis were enrolled. Eighty-nine candidate single nucleotide polymorphisms (SNPs) of 49 human cytokine genes were chosen and were analyzed using the iPLEX technique. Competing risk regression was used to identify the factors associated with HBV-RS. Participants had a median age of 66.1 years and 56.7% were male (n = 59). The anti-HBs and anti-HBc positivity rates were 82.4% and 94.1%, respectively, among patients for whom data were available (approximately 81%). A mean of 7.14 cycles of rituximab therapy were administered, and a total of 14 (13.4%) patients developed HBV-RS. Nine SNPs showed significant differences in frequency between patients with or without HBV-RS: CD40 rs1883832, IL4 rs2243248 and rs2243263, IL13 rs1295686, IL18 rs243908, IL20 rs1518108, and TNFSF13B rs12428930 and rs12583006. Multivariate analysis showed that ≥6 cycles of rituximab therapy, IL18 rs243908, and the IL4 haplotype rs2243248∼rs2243263 were independently associated with HBV-RS. The IL4 haplotype rs2243248∼rs2243263 was significantly associated with HBV-RS regardless of anti-HBs status. Polymorphisms in human cytokine genes impact the risk of rituximab-associated HBV-RS.
- Published
- 2016
- Full Text
- View/download PDF
21. Nonapnea Sleep Disorders and the Risk of Acute Kidney Injury: A Nationwide Population-Based Study.
- Author
-
Lin HY, Chang KT, Chang YH, Lu T, Liang CJ, Wang DC, Tsai JH, Hsu CY, Hung CC, Kuo MC, Lin CS, and Hwang SJ
- Subjects
- Adult, Age Factors, Aged, Cohort Studies, Comorbidity, Female, Humans, Incidence, Male, Middle Aged, Sex Factors, Sleep Wake Disorders epidemiology, Taiwan epidemiology, Acute Kidney Injury epidemiology, Sleep Wake Disorders complications
- Abstract
Nonapnea sleep disorders (NASDs) and associated problems, which are highly prevalent in patients with kidney diseases, are associated with unfavorable medical sequelae. Nonetheless, whether NASDs are associated with acute kidney injury (AKI) development has not been thoroughly analyzed. We examined the association between NASD and AKI. We conducted a population-based study by using 1,000,000 representative data from the Taiwan National Health Insurance Research Database for the period from January 1, 2000, to December 31, 2010. We studied the incidence and risk of AKI in 9178 newly diagnosed NASD patients compared with 27,534 people without NASD matched according to age, sex, index year, urbanization level, region of residence, and monthly income at a 1:3 ratio. The NASD cohort had an adjusted hazard ratio (hazard ratio [HR]; 95% confidence interval [CI] = 1.15-2.63) of subsequent AKI 1.74-fold higher than that of the control cohort. Older age and type 2 diabetes mellitus were significantly associated with an increased risk of AKI (P < 0.05). Among different types of NASDs, patients with insomnia had a 120% increased risk of developing AKI (95% CI = 1.38-3.51; P = 0.001), whereas patients with other sleep disorders had a 127% increased risk of subsequent AKI (95% CI = 1.07-4.80; P = 0.033). Men with NASDs were at a high risk of AKI (P < 0.05). This nationwide population-based cohort study provides evidence that patients with NASDs are at higher risk of developing AKI than people without NASDs.
- Published
- 2016
- Full Text
- View/download PDF
22. The White Matter Microintegrity Alterations of Neocortical and Limbic Association Fibers in Major Depressive Disorder and Panic Disorder: The Comparison.
- Author
-
Lai CH and Wu YT
- Subjects
- Adult, Case-Control Studies, Cross-Sectional Studies, Diffusion Tensor Imaging, Female, Humans, Male, Middle Aged, Depressive Disorder, Major pathology, Limbic Lobe pathology, Neocortex pathology, Panic Disorder pathology, White Matter pathology
- Abstract
The studies regarding to the comparisons between major depressive disorder (MDD) and panic disorder (PD) in the microintegrity of white matter (WM) are uncommon. Therefore, we tried to a way to classify the MDD and PD. Fifty-three patients with 1st-episode medication-naive PD, 54 healthy controls, and 53 patients with 1st-episode medication-naive MDD were enrolled in this study. The controls and patients were matched for age, gender, education, and handedness. The diffusion tensor imaging scanning was also performed. The WM microintegrity was analyzed and compared between 3 groups of participants (ANOVA analysis) with age and gender as covariates. The MDD group had lower WM microintegrity than the PD group in the left anterior thalamic radiation, left uncinate fasciculus, left inferior fronto-occipital fasciculus, and bilateral corpus callosum. The MDD group had reductions in the microintegrity when compared to controls in the bilateral superior longitudinal fasciculi, inferior longitudinal fasciculi, inferior fronto-occipital fasciculi, and corpus callosum. The PD group had lower microintegrity in bilateral superior longitudinal fasciculi and left inferior fronto-occipital fasciculus when compared to controls. The widespread pattern of microintegrity alterations in fronto-limbic WM circuit for MDD was different from restrictive pattern of alterations for PD.
- Published
- 2016
- Full Text
- View/download PDF
23. Using a Harmonic Scalpel "Drilling and Clamping" Method to Implement Zero Ischemic Robotic-assisted Partial Nephrectomy: An Observation Case Report Study.
- Author
-
Hou CP, Lin YH, Hsu YC, Chen CL, Chang PL, and Tsui KH
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Nephrectomy adverse effects, Postoperative Complications, Prospective Studies, Robotic Surgical Procedures adverse effects, Tomography, X-Ray Computed, Treatment Outcome, Ischemia prevention & control, Kidney blood supply, Kidney Neoplasms surgery, Nephrectomy methods, Robotic Surgical Procedures methods
- Abstract
Robot-assisted partial nephrectomy (RAPN) has gradually become a popular minimally invasive nephron-sparing surgical option for small renal tumors. Ischemic injury should be minimized because it impacts renal function outcomes following partial nephrectomy. Herein, the authors detail the technique and present initial perioperative outcomes of our novel harmonic scalpel "drilling and clamping" method to implement zero-ischemic RAPN. The authors prospectively collected baseline and perioperative data of patients who underwent zero ischemic RAPN performed by our harmonic scalpel "drilling and clamping" method. From April 2012 to December 2014, a total of 19 consecutive zero ischemic RAPN procedures were performed by a single surgeon. For 18 of the 19 patients, RAPN using our harmonic scalpel "Drilling and Clamping" method was successfully completed without the need for hilar clamping. The median tumor size was 3.4 cm (range: 1.8-6.2); operative time was 3.2 hours (range: 1.9-4.5); blood loss was 100 mL (range: 30-950); and postoperative hospital stay was 4 days (3-26). One patient required intraoperative blood transfusion. Two patients had intra or postoperative complications: 1 was converted to traditional laparotomy because of massive bleeding, whereas another had postoperative stress ulcer. Pathology confirmed renal cell carcinoma in 13 patients (63.2%), angiomyolipoma in 6 patients: (31.5%), and oncocytoma in 1 patient (5.3%). Mean pre- and postoperative serum creatinine (0.82 mg/dL and 0.85 mg/dL, respectively), estimated glomerular filtration rate (84.12 and 82.18, respectively), and hemoglobin (13.27 g/dL and 12.71 g/dL, respectively) were comparable. The authors present a novel zero-ischemic technique for RAPN. They believe that this technique is feasible and reproducible., Competing Interests: The authors have no funding and conflicts of interest to disclose.
- Published
- 2016
- Full Text
- View/download PDF
24. Cardiopulmonary Function, Exercise Capacity, and Echocardiography Finding of Pediatric Patients With Kawasaki Disease: An Observational Study.
- Author
-
Tuan SH, Li MH, Hsu MJ, Tsai YJ, Chen YH, Liao TY, and Lin KL
- Subjects
- Adolescent, Age Factors, Case-Control Studies, Child, Child, Preschool, Female, Heart Function Tests, Humans, Male, Prognosis, Reference Values, Respiratory Function Tests, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Factors, Echocardiography, Doppler methods, Exercise Test methods, Exercise Tolerance physiology, Mucocutaneous Lymph Node Syndrome diagnosis
- Abstract
Coronary artery (CA) abnormalities influence exercise capacity (EC) of patients with Kawasaki disease (KD), and Z-score of CA is a well established method for detecting CA aneurysm. We studied the influence of KD on cardiopulmonary function and EC; meanwhile we analyzed echocardiographic findings of KD patients. We also assessed the correlation between CA Z-score and EC of KD patients to see if CA Z-score of KD patients could reflect EC during exercise.Sixty-three KD patients were recruited as KD group 1 from children (aged 5-18 y) who received transthoracic echocardiographic examinations and symptom-limited treadmill exercise test for regular follow-up of KD from January 2010 to October 2014 in 1 medical center. We then divided KD group 1 into KD group 2 (<5 y, n = 12) and KD group 3 (≥5 y, n = 51) according to time interval between KD onset to when patients received test. Control groups were matched by age, sex, and body mass index. Max-Z of CA was defined as the maximal Z-score of the proximal LCA or RCA by Dalliarre equation or Fuse calculator.All routine parameters measured during standard exercise test were similar between KD and control groups, except that peak rate pressure products (PRPPs) in KD group 1 to 3 were all lower than corresponding control groups significantly (P = 0.010, 0.020, and 0.049, respectively). PRPPs correlated with Max-Z of CA by both equations modest inversely (by Dallaire, P = 0.017, Spearman rho = -0.301; by Fuse, P = 0.014, Spearman rho = -0.309).Our study recruited larger number of KD patients and provided a newer data of EC of KD patients. Our finding suggests that after acute stage of KD, patients could maintain normal cardiorespiratory fitness. Therefore, we believe that it is important to promote cardiovascular health to KD patients and KD patients should exercise as normal peers. However, since KD patients might still have compromised coronary perfusion during exercise, it remains crucial to assess and monitor cardiovascular risk of KD patients. Max-Z of CA correlates with PRPP modest inversely and might be used as a follow-up indicator of CA reserve during exercise after acute stage of KD.
- Published
- 2016
- Full Text
- View/download PDF
25. Behind and Beyond the Masaoka Staging: A 25-Year Follow-up Study of Tumor Recurrence in Completely Resected Thymic Epithelial Tumors in a Single Institution.
- Author
-
Tseng YL, Chang JM, Lai WW, Chang KC, Lee SC, Lin SH, and Yen YT
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Survival Analysis, Taiwan epidemiology, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local epidemiology, Neoplasms, Glandular and Epithelial epidemiology, Neoplasms, Glandular and Epithelial pathology, Neoplasms, Glandular and Epithelial surgery, Thymectomy adverse effects, Thymectomy methods, Thymus Neoplasms epidemiology, Thymus Neoplasms pathology, Thymus Neoplasms surgery
- Abstract
We analyzed prognosticators for recurrence and post-recurrence survival in completely resected thymic epithelial tumors for the past 25 years in a single institution.Between June 1988 and December 2013, 238 patients undergoing intent-to-treat surgery for thymic epithelial tumors were reviewed. Sex, age, myasthenia gravis (MG), tumor histology, Masaoka staging, characteristic of locoregional invasion and recurrence, and the treatment for recurrence were collected. Comparison between groups was conducted using the Student t test and χ test. Survival analysis was performed using the Kaplan-Meier method and log-rank test. The Cox proportional hazards model was used for univariate and multivariate analyses of prognostic factors.One hundred sixteen of 135 patients with completely resected thymoma and 35 of 56 patients with thymic carcinoma remained free of recurrence. In patients with completely resected thymoma, Masaoka staging, MG, tumor invasion into the lung, pericardium, and innominate vein or superior vena cava (SVC) invasion were associated with recurrence-free survival in univariate analysis (P = 0.004, 0.003, 0.001, 0.007, and 0.039, respectively). In multivariate analysis, MG was the positive independent prognosticator (P = 0.039). In patients with completely resected thymic carcinoma, Masaoka staging and innominate vein or SVC invasion were associated with recurrence-free survival in univariate analysis (P = 0.045 and 0.005, respectively), whereas innominate vein or SVC invasion was the negative independent prognosticator (P = 0.012). In patients with recurrent thymoma, those treated with surgery followed by chemotherapy had a significantly better post-recurrence survival than those undergoing chemoradiotherapy (P = 0.029) and those without treatment (P = 0.007). Patients with recurrent thymic carcinoma undergoing surgery followed by chemotherapy had a significantly better post-recurrence survival than those without treatment (P = 0.004), but not significantly better than those undergoing chemoradiotherapy (P = 0.252).In patients with completely resected thymoma, MG was the positive independent prognosticators of recurrence-free survival. Surgery should be attempted for recurrent disease for better post-recurrence survival. In patients with completely resected thymic carcinoma, innominate vein or SVC invasion was the negative independent prognosticator. Surgery for recurrence could be considered since it provided benefit for post-recurrence survival as chemoradiotherapy did., Competing Interests: The authors have no funding and conflicts of interest to disclose.
- Published
- 2015
- Full Text
- View/download PDF
26. Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma.
- Author
-
Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, Chen PM, Chiou TJ, Liu JH, Liu YC, and Liu CJ
- Subjects
- Age Factors, Aged, Female, Health Status, Humans, Male, Middle Aged, Mortality, Premature, Multiple Myeloma complications, Retrospective Studies, Risk Factors, Sex Factors, Survival Rate, Taiwan, Multiple Myeloma diagnosis, Multiple Myeloma mortality
- Abstract
The overall survival of patients with multiple myeloma (MM) has been improved greatly over the last 2 decades with the broader use of novel drugs and autologous tandem transplantation. However, more than one tenth of myeloma patients still die shortly after diagnosis. We therefore aim to investigate the risk factors of early mortality (death within 60 days after diagnosis) in patients with MM. We included in this study 451 consecutive patients with MM, newly diagnosed at an Asian tertiary medical center between January 1, 2002 and April 30, 2015. A total of 57 subjects who experienced early mortality were identified. Risk factors for early mortality in myeloma patients were collected and analyzed. Early mortality occurred in 57 (12.6%) of the myeloma patients. In the multivariate analysis, being male (adjusted OR 2.93, 95% CI 1.17-7.31), serum albumin < 3.5 g/dL (adjusted OR 2.71, 95% CI 1.09-6.74), primary plasma cell leukemia (adjusted OR 17.61, 95% CI 1.01-306.05), serum albumin (adjusted OR 2.70, 95% CI 1.15-6.38), corrected serum calcium ≥ 12 mg/dL (adjusted OR 2.94, 95% CI 1.21-7.14), and LDH ≥ 250 U/L (adjusted OR 3.07, 95% CI 1.50-6.27) were identified as independent risk factors of early mortality. Pneumonia with other infections contributed most to early mortality (n = 36, 65%), followed by renal failure and cardiac failure. The early mortality rate is high (12.6%) in patients with MM. Patients who are male and those with primary plasma cell leukemia, low serum albumin, high-corrected serum calcium, or LDH are at risk of early mortality. Nearly two thirds of the myeloma patients who experienced early mortality in our study (37 of 57, 65%) died of infection. Once a high-risk group is identified, much effort is required to target new approaches for prevention, early detection, and treatment of infections., Competing Interests: The authors have no conflicts of interest to disclose.
- Published
- 2015
- Full Text
- View/download PDF
27. Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection.
- Author
-
Wu CY, Fu JY, Wu CF, Hsieh MJ, Liu YH, Wu YC, Yang CT, and Tsai YH
- Subjects
- Age Factors, Aged, Carcinoma, Non-Small-Cell Lung pathology, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Lung Neoplasms pathology, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Pleura pathology, Prognosis, Risk Factors, Survival Rate, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms mortality, Lung Neoplasms surgery, Pneumonectomy mortality
- Abstract
The current TNM staging system did not provide disease relapse information. The aim of study was try to establish a predictive survival model for disease and overall survival in nonsmall cell lung cancer patients who presented as resectable disease and to develop a reference for follow-up imaging tool selection.From January 2005 to December 2011, 442 patients who initially presented as resectable disease (stages I-IIIa) and received anatomic resection and mediastinal lymph node dissection were included in the study.Medical charts were thoroughly reviewed and clinico-pathologic factors were collected and analyzed.Visceral pleural invasion, tumor size >5 cm, and postoperative adjuvant therapy were identified as risk factors for poorer disease-free survival. The 5-year disease-free survival from score 0 to 3 was 68.7%, 46.6%, 31.9%, and 26.1%, respectively. The disease relapse percentage for scores 0 to 3 were 26.49%, 50.61%, 65.05%, and 73.81%, respectively. For analysis of overall survival, age >60 years, tumor size >3 cm, and total metastatic lymph node ratio >0.05 were correlated to worse overall survival. Because greater age may be correlated with poor general condition, we re-scored risk factors that correlated to disease severity that ranging from 0 to 2. The 5-year overall survival range from score 0 to 2 was 56.3%, 43.1%, and 13.1%, respectively.Poor prognostic factors correlated to disease-free survival were tumor size >5 cm, visceral pleural invasion, and patients needing to receive postoperative adjuvant therapy. Disease-free survival of resectable nonsmall cell lung cancer patients and disease relapse can be stratified by these 3 factors. Chest tomography may be recommended for patients with 1 or more poor disease-free survival risk factors.
- Published
- 2015
- Full Text
- View/download PDF
28. When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?: A Nomogram-guided Treatment Strategy.
- Author
-
Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, and Huo TI
- Subjects
- Aged, Carcinoma, Hepatocellular mortality, Female, Hepatectomy, Humans, Liver Neoplasms mortality, Male, Middle Aged, Nomograms, Propensity Score, Retrospective Studies, Survival Analysis, Taiwan epidemiology, Carcinoma, Hepatocellular surgery, Catheter Ablation, Liver Neoplasms surgery, Neoplasm Recurrence, Local epidemiology
- Abstract
Radiofrequency ablation (RFA) is indicated for early-stage hepatocellular carcinoma (HCC), but the comparative efficacy between RFA and surgical resection (SR) is inconclusive. We aim to develop a prognostic nomogram for predicting recurrence-free survival (RFS) after RFA. We also evaluate the possibility of using nomogram in improving treatment algorithm.We retrospectively enrolled 836 patients with Barcelona Clínic Liver Cancer very-early/early-stage HCC receiving SR or RFA. A visually-orientated nomogram was constructed with Cox proportional hazards model, and number and size of tumor, platelet count, albumin level, and model for end-stage liver disease score were included. The concordance index of the nomogram was 0.69.Radiofrequency ablation patients were stratified into low and high-risk groups by the median of nomogram scores. The RFS and overall survival (OS) of 2 risk groups were compared with SR patients with propensity score matching analysis. SR provided better RFS and OS compared with high-risk (nomogram score ≥9.8) RFA patients in the propensity model. The 5-year RFS rates were 36% versus 11%, whereas the 5-year OS rates were 74% versus 60% for SR and high-risk RFA groups, respectively (both P < 0.05). However, SR was associated with better RFS (5-year RFS rates 41% vs 29%), but similar OS (5-year OS rates 80% vs 81%), compared with low-risk (nomogram score <9.8) RFA patients in the propensity model (P < 0.05 and P > 0.05, respectively).In conclusion, this user-friendly nomogram offers individualized recurrence risk estimation and stratification for early HCC patients receiving curative RFA. The nomogram can be integrated into current treatment algorithm. SR should be considered the first-line treatment for high-risk patients to achieve better long-term survival.
- Published
- 2015
- Full Text
- View/download PDF
29. CT-Guided Percutaneous Radiofrequency Thermocoagulation for Recurrent Trigeminal Neuralgia After Microvascular Decompression: A Cohort Study.
- Author
-
Lai GH, Tang YZ, Wang XP, Qin HJ, and Ni JX
- Subjects
- Adult, Aged, Decompression, Surgical methods, Humans, Middle Aged, Recurrence, Retrospective Studies, Tomography, X-Ray Computed, Treatment Outcome, Trigeminal Neuralgia etiology, Decompression, Surgical adverse effects, Electrocoagulation methods, Surgery, Computer-Assisted, Trigeminal Neuralgia surgery
- Abstract
This article evaluates the long-term outcomes of computed tomography (CT)-guided percutaneous radiofrequency thermocoagulation (PRT) for patients with recurrent trigeminal neuralgia (TN) after microvascular decompression (MVD).This is a retrospective study of 41 patients with intractable TN who after MVD underwent CT-guided PRT procedures between 2002 and 2012.The mean length of follow-up after PRT was 44.4 months. Immediate pain relief was in 37 patients (90.2%); the percentage of patients who remained in "excellent" or "good" pain relief condition after CT-guided PRT procedure was 85% at 1 year, 80% at 2 years, 51% at 5 years, and 41% at 10 years. Six patients received the second PRT and all achieved "excellent" or "good" pain relief. In total, 34 of these patients (82.9%) received multi-PRT procedure and remained satisfied with their pain relief during the follow-up period. Postoperative complications included facial numbness in 36 patients, limited eyes opening in 1 patient, ear paresthesia in 1 patient, no tears in 1 patient, and taste hypesthesia in 1 patient; these symptoms were all improved in the process of follow-up and their life had not severely affected. No mortality was observed during and after CT-guided PRT procedures.CT-guided PRT should be considered as an alternative treatment for patients with recurrent TN after MVD.
- Published
- 2015
- Full Text
- View/download PDF
30. Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System.
- Author
-
Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Chiou YY, Lin HC, and Huo TI
- Subjects
- Aged, Aged, 80 and over, Algorithms, Carcinoma, Hepatocellular classification, Clinical Protocols, Female, Health Status Indicators, Humans, Kidney Function Tests, Liver Function Tests, Liver Neoplasms classification, Male, Middle Aged, Neoplasm Staging, Propensity Score, Proportional Hazards Models, Prospective Studies, Survival Analysis, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular therapy, Liver Neoplasms diagnosis, Liver Neoplasms therapy
- Abstract
Hepatocellular carcinoma (HCC) patients with performance status (PS) 1 or 2 are considered similar in the Barcelona Clinic Liver Cancer (BCLC) system. The rationales are not fully studied. A total of 693 and 335 HCC patients were classified as PS 1 and 2, respectively, in a prospectively followed up database. One-to-one matched pairs between HCC patients were generated by using the propensity score with matching model. Survival analysis was performed and the hazard ratio was calculated with the Cox proportional hazards model. Patients with PS 1 were significantly younger and had better liver and renal functions compared with patients with PS 2 (all P < 0.05). Patients with PS 1 had earlier BCLC stages and higher chances to undergo curative treatments (both P < 0.05). After matching, patients with PS 1 or 2 had similar age, gender, liver diseases, severity of cirrhosis, tumor burden, and treatments (all P > 0.05); patients with PS 1 had significantly better prognosis compared with patients with PS 2 (P < 0.05). There were 68% of patients with PS 1 that underwent aggressive treatments (resection, transplantation, percutaneous ablation, or transarterial chemoembolization), which were significantly correlated to better outcome with a hazard ratio of 0.539 in the matching model (P = 0.002). For patients with PS 2, aggressive treatments were not significantly associated with better long-term survival. Aggressive treatments provide survival benefits for patients with PS 1, but not for patients with PS 2. HCC patients with PS 1 or 2 should be considered clinically different disease entities in the BCLC system.
- Published
- 2015
- Full Text
- View/download PDF
31. Use of Extracorporeal Membrane Oxygenation to Rescue Patients With Refractory Ventricular Arrhythmia in Acute Myocardial Infarction.
- Author
-
Yeh CF, Wang CH, Tsai PR, Wu CK, Lin YH, and Chen YS
- Subjects
- Female, Follow-Up Studies, Hospital Mortality trends, Humans, Male, Middle Aged, Myocardial Infarction mortality, Retrospective Studies, Risk Factors, Survival Rate trends, Tachycardia, Ventricular etiology, Tachycardia, Ventricular mortality, Taiwan epidemiology, Treatment Outcome, Extracorporeal Membrane Oxygenation methods, Myocardial Infarction complications, Patient Admission trends, Tachycardia, Ventricular therapy
- Abstract
Refractory ventricular arrhythmia is a serious problem in acute myocardial infarction (AMI), with an extremely high mortality rate and limited effective treatment. Extracorporeal membrane oxygenation (ECMO) is useful to rescue patients with cardiopulmonary collapse. However, little is known about whether ECMO is a potential rescue technique for patients with refractory ventricular arrhythmia in AMI.We retrospectively analyzed prospectively collected data on patients with AMI and refractory ventricular arrhythmia who underwent ECMO as rescue therapy and the bridge to revascularization from February 2001 to January 2013. Primary endpoint was mortality on index admission, and secondary endpoint was mortality on index admission or advanced brain damage at discharge.A total of 69 (62 men) patients were enrolled in this study. During the index admission, 39 patients (56.5%) met primary endpoint, and 45 patients (65.2%) met secondary endpoint, respectively. In multivariate Cox regression analysis, both the presence of profound anoxic encephalopathy and acute renal failure requiring dialysis were significant predictive factors for both primary and secondary endpoints.ECMO is a feasible rescue therapy and bridge to revascularization in patients with refractory ventricular arrhythmia in acute myocardial infarction. The presence of profound anoxic encephalopathy and acute renal failure requiring dialysis were significant prognostic factors.
- Published
- 2015
- Full Text
- View/download PDF
32. Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size.
- Author
-
Ho CM, Hu RH, Lee PH, Wu YM, and Ho MC
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular pathology, Cause of Death, Female, Humans, Liver Neoplasms pathology, Male, Middle Aged, Multivariate Analysis, Retrospective Studies, Risk Factors, Taiwan epidemiology, Carcinoma, Hepatocellular mortality, Liver pathology, Liver Neoplasms mortality, Neoplasm Recurrence, Local mortality
- Abstract
Insufficient data are available regarding the validation of long-term survival in patients with T2 (solitary tumor with microvascular invasion [MVI] or multiple tumors, none >5 cm) hepatocellular carcinoma (HCC) after primary hepatectomy. We aim to evaluate the survival and relevant risk factors for T2 HCC patients. Between 2001 and 2007, 312 T2 HCC patients who underwent primary hepatectomy were included. Survival was estimated using the Kaplan-Meier method and compared using Cox proportional hazard model with adjusted independent prognostic factors. The 1, 3, and 5-year overall survival rates of patients with MVI were 85.7%, 68.7%, and 64.8%, respectively; these were inferior to the rates in patients without MVI, which were 93.0%, 89.3%, and 73.7%, respectively (P = 0.037). Within the with-MVI group, the survival rate of patients with tumor sizes ≥ 5 cm was inferior to that of patients with tumors <5 cm (overall, P = 0.01; recurrence-free, P < 0.0001). For patients with the largest tumors in the <5-cm group, those without MVI tended to have a higher probability of recurrence for 2 years after resection (P = 0.088) but a similar overall survival rate relative to those with MVI (P = 0.31). The crude metastasis-free survival was higher in the without-MVI group than in the with-MVI group (P = 0.012). The T2 HCC category comprised heterogeneous patients with differences in survival rates. Extrahepatic recurrence occurred more frequently in patients with MVI than in those without MVI. These results provide evidence for an updated definition of T2 HCC.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.